ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 1 of 111  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled   
  
 
Clinical Investigation Plan  
Clinical Investigation Plan/Study Title  ArcticLine Feasibility Study  
Clinical Investigation Plan Identifier  MDT16015  
Study Product Name  [CONTACT_169307]™ Cardiac Cryoablation Catheter  
Sponsor/Local Sponsor  [LOCATION_002]  
Medtronic, Inc.  
[ADDRESS_197599]  
Brampton, Ontario, L6Y 0R3  
[PHONE_3691] -460 -3800  
Document Version  Version 1.0, 14JUN2017  
Lead Principal Investigator(s)  Frank Pelosi, MD  
Associate Professor of Medicine 
Director, Electrophysiology Fellowship 
Program  
University of Michigan  
CVC Cardiovascular Medicine  
[ADDRESS_197600], CVC #2554 
Ann Arbor, MI [ZIP_CODE] -5853  
Telephone: 734 -232 -0112  
Fax: 734 -936 -7026  
Email: [EMAIL_3384]  
Confidentiality Statement  
The information contained in this document is confidential and the proprietary property of 
Medtronic. Any distribution, copying, or disclosure without the prior written authorization of 
Medtronic is strictly prohibited. Persons to whom the information is d isclosed must know that it 
is confidential and that it may not be further disclosed by [CONTACT_476].  

ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page [ADDRESS_197601]  Information  ................................ ................................ ................................ .........  7 
1. Glossary  ................................ ................................ ................................ ...............................  8 
2. Synopsis  ................................ ................................ ................................ ............................  10 
3. Introduction  ................................ ................................ ................................ .......................  16 
3.1. Background  ................................ ................................ ................................ ........................  16 
3.2. Purpose  ................................ ................................ ................................ .............................  19 
4. Objectives  and  Endpoints  ................................ ................................ ................................ ..... 20 
4.1. Objectives  ................................ ................................ ................................ ..........................  20 
4.1.1.  Primary  Objective(s)  ................................ ................................ ................................ ............  20 
4.1.2.  Ancillary  Objective  #1 ................................ ................................ ................................ .........  20 
4.1.3.  Ancillary  Objective  #2 ................................ ................................ ................................ .........  21 
4.1.4.  Ancillary  Objective  #3 ................................ ................................ ................................ .........  21 
4.1.5.  Ancillary  Objective  #4 ................................ ................................ ................................ .........  21 
4.1.6.  Ancillary  Objective  #5 ................................ ................................ ................................ .........  21 
4.1.7.  Ancillary  Objective  #6 ................................ ................................ ................................ .........  22 
4.1.8.  Ancillary  Objective  #[ADDRESS_197602]  Consent  ................................ ................................ ................................ ..................  38 
8.3. Baseline and  Pre -Ablation  Procedure  ................................ ................................ ......................  40 
8.4. Procedure  ................................ ................................ ................................ ..........................  41 
8.4.1.  High Level  Procedure  Overview  ................................ ................................ ....................  41 
8.4.2.  Esophageal Visualization and Temperature  Monitoring  ................................ ....................  42 
8.4.3.  Peri -Procedural  Anticoagulation  ................................ ................................ ...................  43 
8.4.4.  Diaphragm  Movement  ................................ ................................ ................................ . 43 
8.4.5.  Pulmonary Vein Cryoablation with Arctic Front  Advance Catheter  ................................ ..... 43 
8.4.6.  Linear Cryoablation with ArcticLine Catheter: Roof and  Posterior  Wall ...............................  44 
8.4.7.  Linear Cryoab lation with ArcticLine Catheter:  Mitral  Isthmus  ................................ ............  45 
8.4.8.  Linear Cryoablation with ArcticLine Catheter:  Cavotricuspid  Isthmus  ................................  [ADDRESS_197603] Withdrawal or Discontinuation  ................................ ................................ ...................  53 
9. Risks  and  Benefits  ................................ ................................ ................................ ...............  54 
9.1. Potential  Risks ................................ ................................ ................................ ....................  54 
9.2. Potential  Benefits  ................................ ................................ ................................ ................  55 
9.3. Risk -Benefit  Rationale  ................................ ................................ ................................ ..........  55 
10. Adverse Events and  Device Deficiencies  ................................ ................................ .................  57 
10.1. Definitions/Classifications  ................................ ................................ ................................ .... [ADDRESS_197604]  Complaints  ................................ ................................ ...........................  68 
11. Clinical  Events  Committee  ................................ ................................ ................................ ... 69 
12. Statistical Design  and  Methods  ................................ ................................ .............................  70 
12.1. Primary  Objective  ................................ ................................ ................................ ................  71 
12.2. Ancillary  Objective  #1 ................................ ................................ ................................ ..........  73 
12.3. Ancillary  Objective  #2 ................................ ................................ ................................ ..........  74 
12.4. Ancillary  Objective  #3 ................................ ................................ ................................ ..........  75 
12.5. Ancillary  Objective  #4 ................................ ................................ ................................ ..........  76 
12.6. Ancillary  Objective  #5 ................................ ................................ ................................ ..........  77 
12.7. Ancillary  Objective  #6 ................................ ................................ ................................ ..........  78 
12.8. Ancillary  Objective  #7 ................................ ................................ ................................ ..........  79 
ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 5 of 111  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled   
 13. Ethics  ................................ ................................ ................................ ................................  80 
13.1. Statement(s) of  Compliance  ................................ ................................ ................................ . [ADDRESS_197605] Retention  and  Reports  ................................ ................................ ...............................  85 
14.7. Publication and Use  of Information  ................................ ................................ .........................  92 
14.8. Suspension or  Early  Termination  ................................ ................................ ...........................  94 
14.8.1.  Early Termination  or Suspension  ................................ ................................ ...................  94 
14.8.2.  Study -Wide Termination  or Suspension  ................................ ................................ .........  94 
14.8.3.  Investigator/Center Termination  or Suspension  ................................ .............................  94 
14.8.4.  Procedures for Termination  or Suspension  ................................ ................................ .... 95 
[IP_ADDRESS].  Medtronic -Initiated and  Regulatory  Authority -Initiated  ................................ ...................  95 
[IP_ADDRESS].  Investigator -Initiated  ................................ ................................ ................................ .. 95 
[IP_ADDRESS].  IRB/REB/MEC -Initiated  ................................ ................................ ................................  95 
15. References  ................................ ................................ ................................ .........................  97 
16. Appendices  ................................ ................................ ................................ .........................  99 
17. Version  History  ................................ ................................ ................................ .................  111 
ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 6 of 111  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled   
  Listing of  Tables   
Table 1: Study Sponsor and Monitoring  Contact  [CONTACT_7171]  ................................ ................................  7 
Table 2:  Device  Information  ................................ ................................ ................................ .....................  27 
Table 3: Study Procedures and Data Collection by  [CONTACT_169253]  ................................ ..........................  37 
Table 4:  Required Phrenic  Nerve  Pacing  ................................ ................................ ................................ . 43 
Table 5:  Follow -up Schedule  ................................ ................................ ................................ ...................  49 
Table 6:  Adverse Event and Device  Deficiency  Definitions  ................................ ................................ .. 57 
Table 7: Adverse Event  Reporting  Requirements  ................................ ................................ ..................  64 
Table 8:  Adverse Event  Classification  Responsibilities  ................................ ................................ .........  66 
Table 9: Device Deficiency  Reporting  Requirements  ................................ ................................ ............  67 
Table 10: Investigator reports applicable for all geographies per  Medtronic  requirements  ..............  86 
Table 11: Additional Investigator reports applicable to the  United  States  ................................ .................  87 
Table 12: Sponsor reports for the  United  States  ................................ ................................ ...................  89 
Table 13: Sponsor reports  for Canada  ................................ ................................ ................................ ........  91 
Table 14: Foreseeable  adverse  events  ................................ ................................ ................................ .. 101 
Table 15: Adverse  Event  Definitions  ................................ ................................ ................................ ..... 104 
 
 Listing of  Figures   
Figure 1:  Study  Design  Flowchart  ................................ ................................ ................................ ...........  24 
 
 Listing of  Appendices   
Appendix A: CryoConsole  Investigational  Label  ................................ ................................ ....................  99 
Appendix B: Instructions  For  Use ................................ ................................ ................................ ...........  100 
Appendix C: Foreseeable  Adverse  Events  ................................ ................................ ............................  101 
Appendix D: Endpoint -Related Adverse  Event  Definitions  ................................ ................................ . 104 
Appendix E: Draft Data Collection Elements (Case  Report  Forms)  ................................ ....................  106 
Appendix F: Informed  Consent  Templat e ................................ ................................ .............................  107 
Appendix G:  IRB/REB/MEC  List ................................ ................................ ................................ ..............  108 
Appendix H: Participating Investigators  and  Institutions  ................................ ................................ .... 109 
Appendix I:  Pre -Clinical  Testing  ................................ ................................ ................................ .............  [ADDRESS_197606] information will be sent to the 
centers as needed.  
 
Table 1: Study Sponsor and Monitoring Contact [CONTACT_169254], Clinical Research Specialist 
Direct Phone: [ADDRESS_197607]               Fax:               763 -367 -1727 
Email : [EMAIL_3385]  
Monitoring contacts  
Tina Chen, Principal Clinical Research Monitor 
Direct Phone: 909 -274 -7993  
Email: [EMAIL_3386]  Sponsor Contact [CONTACT_169255] 1.0,  14JUN2017  Page [ADDRESS_197608]  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 10 of 111   
  
 
 
Title  ArcticLine Feasibility Study (“Study”)  
Clinical Study Type  Feasibility  
Product Name  [CONTACT_169308] (“ArcticLine Catheter”)  
Sponsor  [LOCATION_002]  
Medtronic, Inc.  
[ADDRESS_197609]  
Brampton, Ontario, L6Y 0R3 Canada  
[PHONE_3691] -460 -3800  
Indication under 
investigation  The proposed indication for the ArcticLine Catheter evaluated in this 
Study is as follows:  
 
The ArcticLine Cardiac Cryoablation Catheter is indicated for creating 
endocardial linear lesions, subsequent to successful pulmonary vein 
isolation, during cardiac  ablation procedures for treatment of patients 
with persistent atrial fibrillation. The ArcticLine Catheter can also be used 
to treat typi[INVESTIGATOR_169208].  
Investigation 
Purpose  Collect preliminary safety and effectiveness data on the ArcticLine 
Catheter  
Product Status    
Component  Model Number  Geography   
ArcticLine™ Cardiac 
Cryoablation Catheter  2AL35  Canada (investigational) 
US (investigational)   
CryoConsole™, 
including Accessories  106A3, Models 
[ZIP_CODE] -008 -04 or  
[ZIP_CODE] -008 -08 Canada (commercial) 
US (commercial)   
ArcticLine™ Catheter 
File  Not applicable  Canada (investigational) 
US (investigational)   
FlexCath® Advance 
Steerable Sheath 12 Fr  4FC12  Canada (investigational) 
US (investigational)   
Arctic Front Advance® 
Cardiac Cryoablation 
Catheter  2AF233  Canada (commercial)   
2AF283  Canada (commercial)   
2AF234  US (investigational)   
2AF284  US (investigational)   2. Synopsis  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 11 of 111   
  
  
Component  Model Number  Geography   
Freezor® MAX Cardiac 
Cryoablation Catheter  209F3  Canada (commercial)   
209F5  Canada (commercial)   
239F3  US (investigational)   
239F5  US (investigational)   
 Primary 
Objective(s)  Estimate the incidence of ArcticLine Catheter -related and ArcticLine 
cryoablation procedure -related serious adverse events (SAEs) with an 
onset date within [ADDRESS_197610] -procedure  
Ancillary 
Objective(s)  There are seven (7) ancillary objectives for the study, as follows:  
1. Estimate the percentage of patients with acute treatment success of 
the ArcticLine Catheter at the left atrial roof and posterior wall in 
patients with demonstrated entrance block of all p ulmonary veins  and 
who  underwent  roof  and  posterior  wall  ablation  with  ArcticLine.  
2. Estimate the percentage of patients with acute treatment success of 
the ArcticLine Catheter at the mitral isthmus in patients who 
underwent mitral isthmus ablation with  ArcticLine.  
3. Estimate the percentage of patients with acute treatment success of 
the Arc ticLine Catheter at the CTI in patients who underwent CTI 
ablation with  ArcticLine.  
4. Characterize chronic treatment success of the ArcticLine Catheter  in 
patients with demonstrated entrance block of all pulmonary  veins.  
5. Estimate the incidence of ArcticLine Catheter -related and ArcticLine 
cryoablation procedure -related serious adverse events (SAE) through 
the 12 month  visit.  
6. Characterize procedural data (e.g. procedure time, fluoroscopy  time, 
fluoroscopy dose, number of applications, left atrial dwell  time)  
7. Estimate the incidence of adverse events through the 12 month  visit 
that meet the following, as defined in the Clinical Investigation  Plan:  
• Atrioesophageal  fistula  
• Cardiac  perforation/tamponade  
• Cerebrovascular  accident  
• Coronary artery  spasm  
• Death  
• Esophagea l injury  
• Lung injury (including  hemoptysis)  
• Major  bleeding  
• Myocardial  infarction  
• Pericarditis  
• Phrenic nerve injury (ongoing from hospi[INVESTIGATOR_47850])  
• Pulmonary vein  stenosis  
• Symptomatic persistent iatrogenic atrial septal  defect  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 12 of 111   
  
 • Transient ischemic  attack  
• Vagal nerve  injury  
• Vascular access  complications  
Study Design  The study is a prospective, interventional, multi -center, non -randomized, 
single arm, unblinded clinical study. Adult subjects with history of 
persistent atrial fibrillation (AF), including those with concomitant typi[INVESTIGATOR_169209] (AFL), to undergo ab lation of:  
• Pulmonary veins (required, unless prior successful pulmonary  vein 
isolation confirmed at start of study  procedure),  
• Left atrial roof and posterior wall  (required)  
• Mitral isthmus (optional, as determined by [CONTACT_1697]),  and  
• Cavo -tricuspid isthmus (required if subject has a history of AFL or 
AFL is induced during the study procedure, otherwise optional as 
determined by  [CONTACT_1697]).  
 
Study subjects from all partici pating geographies will be followed for 12 
months after the index ArcticLine procedure and will be exited from the 
study at the conclusion of the 12 month follow -up visit.  
Sample Size  Up to 30 subjects will be treated with the ArcticLine Catheter  
Inclusion/ 
Exclusion Criteria  Inclusion Criteria  
• Symptomatic persistent AF, defined as continuous AF that is 
sustained beyond 7 days and documented via consecutive ECG 
recordings  
• Age 18 through 80 years  old 
• Failure  or intolerance  of at least  one  Class  I or III antiarrhythmic 
drug  
• Subject is able and willing to consent to participate in the study 
and will commit to completion of all follow -up requirements  
 
Exclusion Criteria  
• Longstanding persistent AF, defined as continuous AF greater 
than12 month  duration  
• Left atrial diameter greater than 5.0  cm 
• Active systemic  infection  
• History of thromboembolic event within the past 6 months or 
evidence of intracardiac thrombus at the time of the  procedure  
• Prior left atrial ablation attempt, with exception  of: 
o Any pulmonary vein isolation attempt to treat AF,  or 
o Successful ablation to treat Wolff -Parkinson White 
syndrome  
• History of left atrial  tachycardia  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 13 of 111   
  
• History of cardiac ablation within 90 days of planned clinical  study 
procedure  
• Planned concomitant ventricular  ablation1 
• Cryoglobulinemia  
• Structural heart disease of clinical significance  including:  
o NYHA Class IV Heart  Failure  
o Diagnosed with NYHA Class III Heart Failure for more  than 
six months at time of the study ablation  procedure  
o LVEF less than  35%  
o Any cardiac surgery (e.g. CABG) within 3 months of the 
ablation  procedure  
o Any mechanical heart valve, prior aortic or tricuspid valve 
replacement (e.g. valvotomy, valve replacement) or 
tricuspid valve  repair  
o Severe mitral valve regurgitation or  stenosis  
o Significant congenital anomaly or anatomy unable  to 
accommodate  device  
• Prior  surgical maze  procedure  
• Unstable  angina  
• Myocardial infarction within 3 months of the ablation  procedure  
• Presence of primum or secundum atrial septal  defect  
• Anomalous pulmonary venous  return  
• Prior surgery for congenital heart disease including atrial  septal 
defect  repair  
• Hypertrophic cardiomyopathy with LV septal wall thickness >1.5 
cm 
• Uncontrolled  hyperthyroidism  
• Thrombocytosis, thrombocytopenia (including history of heparin - 
induced  thromboc ytopenia)  
• Severe comorbidity or poor general physical/mental health that,  in 
the opi[INVESTIGATOR_871], will not allow the subject to be a 
good study  candidate  
• History of blood clotting or bleeding  abnormalities  
• Contraindication to all anticoagulatio n (e.g. novel oral 
anticoagulants, heparin or  warfarin)  
• Pregnant, nursing or planning to become pregnant during study 
duration  
• Enrollment in another clinical trial without prior approval  from 
Medtronic  
• Presence or use of left atrial appendage closure  device  
 
 
[ADDRESS_197611] at the time of the procedure as assessed by [CONTACT_16032]. However, the ArcticLine Catheter may 
not be used for these purposes.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 14 of 111   
  
 • Presence of or planned implantation of a pacemaker,  implantable 
cardiac defibrillator, implantable loop recorder or cardiac 
resynchronization device with pe rmanent lead  placement  
• Pre -existing hemidiaphragmatic  paralysis  
• Life expectancy less than one  year  
• Known drug or alcohol  dependency  
• Existing pulmonary vein  stent(s)  
Study Procedures 
and Assessments    
 
Bas eline 
 
Proce dure  
 
Pre-Discharge 
 
1 week1 
 
3 mon th2 
6 mon th2 
12 mon th2 
Unscheduled  
Repeat Ab lation 
after Blank ing  
Informed Consent  X          
Inclusion/Exclusion 
Criteria  X          
Medical History  X          
Physical Exam  X          
AAD &  
Anticoagulation 
Medication Review   
X   
X  
X  
X  
X  
X  
X   
Pregnancy Screen3 X          
Arrhythmia 
Symptom Review  X   X X X X X   
Transthoracic 
Echocardiogram 
(TTE)4  
X          
Transesophageal 
Echocardiogram 
(TEE)  X          
12 Lead ECG  X  X  X X X X   
Procedure 
Information   X       X  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 15 of 111   
  
   
 
Bas eline 
 
Proce dure  
 
Pre-Discharge 
 
1 week1 
 
3 mon th2 
6 mon th2 
12 mon th2 
Unscheduled  
Repeat Ab lation 
after Blank ing  
24h Continuous 
Monitoring with 
Holter        
X  
X    
Patient Activated 
Ambulatory ECG 
Monitor      Monthly and symptomatic 
epi[INVESTIGATOR_169210]:  
1Phone visit and/or office visit with Nurse Coordinator  
2Office visit  
3Female subjects of child bearing potential only  
4 Only required if data not available from within 6 months prior to consent date  
Safety 
Assessments  Clinical Events Committee:  
An independent committee comprised of electrophysiologists not 
participating in the study will review and adjudicate all adverse e vents as 
well as all deaths for subjects participating in the study.  
Statistics  No formal hypotheses for this study:  
• Data will be reported as collected and no imputation will  be 
performed for missing or incomplete  observations.  
• Analyses are planned at the following time  points:  
o After completion of the first [ADDRESS_197612] follow -up visits through 12 
month follow -up visit  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 16 of 111   
  
 
 
3.1. Background  
Atrial fibrillation (AF) is a common and disabling cardiac arrhythmia with a heterogeneous clinical 
presentation.  The fundamental pathophysiology consists of atrial wavelets propagating in 
different directions, causing disorganized atrial depolarizations without effective atrial contraction, 
with concomitant rapid and irregular ventricular contractions. As published in the 2017 
HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical 
Ablation of Atrial Fibrillation, there are several  classifications for AF: paroxysmal AF (PAF) is defined 
as AF that terminates spontaneously or with intervention within 7 days of onset; persistent AF is 
defined as continuous AF that is sustained beyond 7 days; and long -standing persistent AF is 
defined a s continuous AF of greater than [ADDRESS_197613] common of the sustained arrhythmias affecting millions of people worldwide. In the 
US, AF affects between 2.7 million and 6.1 million adults3, and that number is expected to double 
over the  next 25 years.4 Prolonged AF may lead to electrical, mechanical, and structural changes to 
the left atrium, which may then progress to tachycardia -induced cardiomyopathy, heart failure 
and/or persistent AF. Persistent AF represents approximately 25% of AF  cases.[ADDRESS_197614] prognosis 
and ischemic cardiomyopathy having a poor prognosis. The mortality rate in patients with AF is 
twice that of patients without AF, and  the risk of AF -related stroke is 5 -fold compared to the risk in 
patients without AF.6   In comparison to patients with PAF, patients with persistent AF are at  a 
 
 
 
 
 
 
 
2 Calkins H, et al., 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Ca theter and 
Surgical Ablation of Atrial Fibrillation, Heart Rhythm (2017), doi:10.[ZIP_CODE]/j.hrthm.2017.05.012.  
3 January C, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of 
the  American  College  of Cardiolo gy/American  Heart  Association  Task  Force  on Practice  Guidelines  and  the  Heart 
Rhythm Society. J Am Coll Cardiol.  2014.  
4 Go A, et al. Prevalence of Diagnosed Atrial Fibrillation in Adults: National Implications for Rhythm Management 
and Stroke Prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 
285(18): 2370 -2375.  
5 Zoni -Berisso  M, et al. Epi[INVESTIGATOR_54360]: European perspective. Clinical Epi[INVESTIGATOR_623]. 
2014;6:213 -220. doi:10.2147/CLEP.S47385.  
6 Wolf P, et al. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 
1991;22(8):983 -988.  3. Introduction  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 17 of 111   
  
significantly greater risk for cardiac mortality (hazard ratio [HR], 2.37; 95% confidence interval [CI], 
1.19 -4.73 ) and all -cause mortality (HR, 1.89; CI, 1.30 -2.74).7 
In the US, approved treatment options for patients with persistent AF are presently limited to 
pharmaceutical therapy and concomitant surgical ablation, which are unsatisfactory for many 
patients with A F.  Per the 2014 AHA/ACC/HRS Guideline for the Management of Patients with 
Atrial Fibrillation, “Antiarrhythmic drug (AAD) efficacy is modest and asymptomatic AF recurrences 
are common ”.3 All AADs may result in adverse events  requiring therapy discontinuation and, with 
the exceptions of amiodarone and propafenone, increase the likelihood of proarrhythmia.2 Side 
effects for AADs include bradycardia, palpi[INVESTIGATOR_814], fatigue, dizziness, nausea and vomiting, 
stomach pain, constipati on and diarrhea, rash, vision problems, and urinary retention. However, 
there is a growing body of evidence supporting catheter ablation as a reasonable option for 
treating persistent AF patients. In 2017, the HRS/EHRA/ECAS/APHRS/SOLAECE Expert 
Consensus S tatement on Catheter and Surgical Ablation of Atrial Fibrillation continued the Class IIa 
Level B recommendation (as previously published in the 2012 HRS/EHRA/ECAS Expert Consensus 
Statement on Catheter and Surgical Ablation of Atrial Fibrillation8) for ca theter and surgical 
ablation of AF for persistent symptomatic AF (refractory or intolerant to at least one Class I or III 
AAD), stating “the benefits of an AF ablation procedure exceed the risks, and that it is reasonable  
to perform AF ablation”.2 In the previously published 2014 AHA/ACC/HRS Guideline for the 
Management of Patients with Atrial Fibrillation, the level of evidence supporting the 
recommendation moved to Class IIa, Level A.[ADDRESS_197615] evolved over time and currently include 
pulmonary vein isolation (PVI) as a cornerstone of ablation therapy in all types of AF (paroxysmal 
and persistent).9, 10 AF arises primarily from the left side of the heart in the atrium, particularly 
where the p ulmonary veins (PVs) join the atrium. The fundamental basis for the AF ablation 
procedure is the elimination of initiating triggers and the creation of myocardial lesions that block  
 
 
7 Ghanbari H, et al. Mortality and cerebrovascular events after radiofr equency catheter ablation of atrial 
fibrillation. Heart Rhythm. 2014;11:1503 -1511.  
8 Calkins H, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial 
Fibrillation: Recommendations for Patient Selection, Procedural  Techniques, Patient Management and Follow -up, 
Definitions, Endpoints, and Research Trial Design. Heart Rhythm 2012;9:632 -696.  
9 Raviele, et al. Venice Chart International consensus Document on Atrial Fibrillation: 2011 Update. J Cardiovasc 
Electrophysiol,  2012;23:890 -923.  
10 Jais P, et al. Stepwise Catheter Ablation of Chronic Atrial Fibrillation: Importance of Discrete Anatomic Sites for 
Termination. J Cardiovasc Electrophysiol . 2006;17: S28 -S36, Suppl. 3.  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197616] been 
developed and applied to the treatment of persistent AF, including: complex fractionated atrial 
electrograms (CFAE), ganglionated plexi, rotors and linear ablation. One such strategy, the 
stepwise approach was introduced over 10 years ago.8,12 The ste pwise strategy assumed that 
better outcomes were obtained when AF was organized and then broke due to additional ablation 
and substrate modification. The strategy was observational in nature and presumed better 
outcomes with a stepwise series of radiofrequ ency (RF) ablations. However, more recently the 
stepwise strategy has been the topic of reevaluation as outcomes may have been more biased by 
[CONTACT_169256].[ADDRESS_197617] randomized control trial to -date looking at outcomes of catheter ablation in the 
persistent AF population, STAR AF II14, demonstrated no significant difference in freedom from AF 
or AF/atrial flutter/atrial tachycardia across three study arms (PVI vs. PVI + complex fractionated 
electrograms vs. PVI + lines).  It is important to note that one of the trial conclusions was the 
statement that “…reason for the lack of benefit associated with additional ablation in our trial is 
unclear”. The question is open as to whether the use of RF ablation technology in the STA R AF II 
trial had an impact on the ability to achieve transmural and contiguous lesions. While an important 
trial in this space, STAR AF II has not definitively answered the question of whether or not lines are 
effective. Subsequently, Kirchhof and Calkins  published a clinical update on catheter ablation in 
patients with persistent atrial fibrillation, stating: “better technology is needed to achieve 
transmural lesions. This has implications not only for the evaluation of linear lesions but also for 
other a blation concepts”. 15 
Medtronic proposes there is a need to investigate the utility of lines using technology (i.e. 
ArcticLine Catheter) capable of creating contiguous, transmural, and durable lesions with fewer 
applications.  ArcticLine is expected to be a safe and effective alternative to the current technology  
 
 
11 Calkins H, et al. HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial 
Fibrillation:  Recommendations for personnel, Policy, Procedures and Follow -Up. Europace . 2007;9(6):335 -379.  
12 Rostock T, et al. Chronic Atrial Fibrilla tion Is a Biatrial Arrhythmia Data from Catheter Ablation of Chronic Atrial 
Fibrillation Aiming Arrhythmia Termination Using a Sequential Ablation Approach. Circ Arrhythmia Electrophysiol. 
2008;1:344 -353.  
13 Winkle RA. How much ablation to eliminate atrial  fibrillation: Is less more or is more more? Heart Rhythm . Epub 
ahead of print. DOI: http://dx.doi.org/10.1016/j.hrthm.2015.06.031  
14Verma A, et al. Approaches to catheter ablation for persis tent atrial fibrillation. N Engl J Med 2015; 372:1812 - 
1822.  
15Kirchof and Calkins. Catheter ablation in patients with persistent atrial fibrillation. European Heart J. 
doi:10.1093/eurheartj/ehw260.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 19 of 111   
  
used to achieve linear ablation (i.e. RF ablation). RF ablation uses a point -by-point approach, 
requiring multiple catheter applications which can leave gaps. We anticipate the safe use of 
ArcticLine in this feasibility study will contribute to planning fu ture clinical evidence activities that 
support the premise that linear ablation can be safe and effective when created with the ArcticLine 
Catheter.  
In regards to patients with a history of cavotricuspid isthmus -dependent flutter, or inducible CTI - 
depende nt atrial flutter at the time of the ablation procedure, the 2017 HRS/EHRA/ECAS Expert 
Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation2 published a Class I 
Level B recommendation for ablation, sta ting it “can be performed safely, easily, and with only a 
slight prolongation in procedure time”. As the clinical evidence is already strong to support the 
success of CTI ablation to treat typi[INVESTIGATOR_169208], Medtronic anticipates that the ArcticLine 
Catheter can be used safely to successfully treat typi[INVESTIGATOR_169211].  
 
3.2. Purpose  
The purpose of the study is to collect preliminary safety and effectiveness data on the ArcticLine 
Catheter when used t o treat persistent AF and right atrial cavotricuspid isthmus dependent atrial 
flutter (“typi[INVESTIGATOR_169208]”). These data will be used to guide subsequent product development 
activities for the ArcticLine Catheter, including feedback on device design an d input into a future 
pi[INVESTIGATOR_2397].  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 20 of 111   
  
 
 
4.1. Objectives  
 
4.1.1.  Primary  Objective(s)  
Estimate the incidence of ArcticLine Catheter -related and ArcticLine cryoablation procedure - 
related serious adverse events (SAEs) with an onset date within [ADDRESS_197618] -procedure, as adjudicated by [CONTACT_34164] (CEC), described as 
follows:  
• Atrioesophageal  fistula  
• Cardiac  perforation/tamponade  
• Cerebrovascular  accident  
• Death  
• Esophageal  injury  
• Major  bleeding  
• Myocardial  infarction  
• Pericarditis  
• Phrenic nerve injury (ongoing at hospi[INVESTIGATOR_47850])  
• Transient ischemic  attack  
• Vagal nerve injury resulting in esophageal dysmotility or  gastroparesis  
• Vascular access  complications  
 
4.1.2.  Ancillary Objective  #1 
Estimate the percentage of patients with acute treatment success of the ArcticLine Catheter at 
the left atrial roof and posterior wall in patients with demonstrated entrance block of all pulmonary 
veins and who underwent roof and posterior wall ablation wi th ArcticLine.  
Ancillary Endpoint #[ADDRESS_197619] confirmed block at the roof line and posterior wall line via periprocedural 
assessment of posterior wall isolation at the completion of the cryoablation procedure to be 
considered an acute treatment s uccess.  4.   Objectives and Endpoints  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinic al Investigation Plan  
Version 1.0,  14JUN2017  Page 21 of 111   
  
4.1.3.  Ancillary Objective  #2 
Estimate the percentage of patients with acute treatment success of the ArcticLine Catheter at 
the mitral isthmus in patients who underwent mitral isthmus ablation with ArcticLine.  
Ancillary Endpoint #[ADDRESS_197620] confirmed bi -directional conductio n block at the mitral isthmus line via 
periprocedural assessment at the completion of the cryoablation procedure to be considered an 
acute treatment success.  
 
4.1.4.  Ancillary Objective  #3 
Estimate the percentage of patients with acute treatment success of the Ar cticLine Catheter at 
the CTI in patients who underwent CTI ablation with ArcticLine.  
Ancillary Endpoint #[ADDRESS_197621] confirmed bi -directional conduction block at the CTI line via periprocedural 
assessment at the completion of the cryoablation proc edure to be considered an acute treatment 
success.  
 
4.1.5.  Ancillary Objective  #4 
Characterize chronic treatment success of the ArcticLine Catheter in patients with demonstrated 
entrance block of all pulmonary veins.  
Ancillary Endpoint #4  
AF/AFL/AT epi[INVESTIGATOR_169212] 30 seconds duration from the end of the 90 day blanking period 
through the 12 month visit.  
 
4.1.6.  Ancillary Objective  #5 
 
Estimate the incidence of ArcticLine Catheter -related and ArcticLine cryoablation procedure - 
related serious adverse events (SAE) through the 12 month visit.  
Ancillary Endpoint #5  
ArcticLine Catheter -related or ArcticLine cryoablation procedure -related SAEs, as adjudicated by 
[CONTACT_34164] (CEC).  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinic al Investigation Plan  
Version 1.0,  14JUN2017  Page 22 of 111   
  
4.1.7.  Ancillary Objective  #6 
Characterize procedural data:  
• Total procedure  time  
• Total ArcticLine Catheter use  time  
• Left atrial dwell  time  
• Total fluoroscopy  time  
• Total fluoroscopy time during ArcticLine Catheter  use  
• Application  duration  
• Number of  applications  
• Fluoroscopy  dose  
 
Ancillary Endpoint #6  
• Total procedure time is defined as time from first venous access to time of last catheter 
removal.  
• Total ArcticLine Catheter use time is defined as cumulative time from each introduction of 
ArcticLine Catheter into the body to its  removal.  
• Left atrial dwell time is defined as time from transseptal puncture to time of removal of last 
sheath/catheter from the left  atrium.  
• Total  fluoroscopy  time  is defined  as total  fluoroscopy  time  used  during  the  procedure.  
• Total fluoroscopy time during Arctic Line Catheter use is defined as the cumulative 
fluoroscopy  time  from each  introduction  of ArcticLine  Catheter  into  the  body  to its 
removal.  
• Application duration is defined as total duration in which cryoablation from the ArcticLine 
Catheter is applied to c ardiac tissue overall and individually to each target  area.  
• Number  of applications  is defined  as the  total  number  of times  in which  the  ArcticLine 
Catheter was used to ablate cardiac tissue overall and individually to each target  area.  
• Total  fluoroscopy  dose  is defined  as the  amount  of radiation  deposited  into  the  tissue, 
measured in Gy or mGy  units.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinic al Investigation Plan  
Version 1.0,  14JUN2017  Page 23 of 111   
  
4.1.8.  Ancillary Objective  #7 
Estimate the incidence of adverse events (AEs) through the 12 month visit.  
 
Ancillary Endpoint #7  
Characterize adverse events through the 12 month visit, described as follows:  
• Atrioesophageal  fistula  
• Cardiac  perforation/tamponade  
• Cerebrovascular  accident  
• Coronary artery  spasm  
• Death  
• Esophageal  injury  
• Lung injury (including  hemoptysis)  
• Major  bleeding  
• Myocardial  infarction  
• Pericarditis  
• Phrenic nerve injury (ongoing from hospi[INVESTIGATOR_47850])  
• Pulmonary vein  stenosis  
• Symptomatic persistent iatrogenic atrial septal  defect  
• Transient ischemic  attack  
• Vagal nerve  injury  
• Vascular access  complications  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinic al Investigation Plan  
Version 1.0,  14JUN2017  Page 24 of 111   
  
 
 
Medtronic is sponsoring the ArcticLine Feasibility Study: a prospective, interventional, multi - 
center, non -randomized, single arm, unblinded clinical study. The goal of the study is to collect 
preliminary safety and ef fectiveness data on the ArcticLine Catheter. The study design diagram is 
shown in Figure 1.  Up to [ADDRESS_197622] 30 ArcticLine Catheters will be used in this study to ensure the s ample size is met. The 
maximum number of subjects that may be treated at a single center is 15 subjects (50% of the total 
treated).  
 
Figure 1:  Study Design Flowchart  
 5.   Study Design  

Medtronic Confidential  
056-F275, v3.[ADDRESS_197623] preliminary safety and effectiveness data of the ArcticLine 
Catheter. Due to the feasibility nature of the study, a comparator arm is not included. There is 
currently no catheter on the market in either Canada or the [LOCATION_002] that is capable of 
creating a linear lesion with a single application.  
A traditional feasibility study with a primary safety objective was chosen for the following reasons:  
 
• The current standard for creating a linear lesion is to use a point -by-point approach with a 
focal catheter and stitch lesions together. This technique has produced mixed clinical 
evidence regarding effectiveness. This study investigates the safety and performance of a 
catheter specifically designed to make linear  lesions.  
• Data  from  the  study  will  be used  to guide  subsequent  product  development  activities  for 
the ArcticLine Catheter, including a potential future pi[INVESTIGATOR_108516].  
 
5.3. Minimization of  Bias  
Selection of subjects, treatment of subjects, and evaluation of study data are potential sources of 
bias. Methods incorporated in the study design to minimize potential bias include (but are not 
limited to):  
• Subjects  will  undergo  screening  to confirm  eligi bility  for enrollment  with  defined 
inclusion/exclusion criteria prior to  enrollment.  
• Subject  demographics  will  be collected  at baseline  to later  assess  possible  characteristics 
that may influence  endpoints.  
• All centers and geographies will use the same version of the CIP and case report  forms.  
• All investigational center personnel and Medtronic personnel will be trained on their 
respective aspects of the study using standardized training  materials.  
• All investi gational center personnel will be trained on and required to follow the  CIP.  
• An independent Clinical Events Committee (CEC) will be utilized to review and adjudicate 
reported adverse events and  deaths.  
• An independent core lab will be utilized to review and  adjudicate the arrhythmia component 
of the ancillary  objectives.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinic al Investigation Plan  
Version 1.0,  14JUN2017  Page 26 of 111   
  
• A statistical analysis plan (SAP) will be developed prior to analyzing data. The plan will 
document all pre -specified analyses and analysis  methods.  
• Monitoring will be conducted to review adherence to the CIP and perform source data 
verification per the Monitoring  Plan.  
• A maximum of [ADDRESS_197624] been 
considered and minimized by [CONTACT_169257], careful study design.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinic al Investigation Plan  
Version 1.0,  14JUN2017  Page 27 of 111   
  
 
 
6.1. General  
Information on the components included in the study are listed in Table 2  and described below. 
Instructions For Use (IFU) of the devices used in the study are provided in their respective manuals.  
There are n o changes to the market -released FlexCath Advance Steerable Sheath (“sheath”), 
CryoConsole, including accessories (with exception of catheter software file), Arctic Front 
Advance Cardiac Cryoablation Catheter, or Freezor MAX Cardiac Cryoablation Catheter d evices 
planned at this time.  
Table 2: Device Information  
 
 
Component  Required 
Use in 
Study?  Model 
Number   
Geography   
Manufacturer  
ArcticLine™ 
Cardiac 
Cryoablation 
Catheter  Yes  2AL35  Canada (investigational) 
US (investigational)  Medtronic CryoCath 
LP 
CryoConsole™, 
including 
Accessories  Yes  106A3,  
Models 
[ZIP_CODE] - 
008 -04 or  
[ZIP_CODE] - 
008 -08 Canada (commercial) 
US (commercial)  
ArcticLine™ 
Catheter File  Yes  Not 
applicable  Canada (investigational) 
US (investigational)  
FlexCath 
Advance® 
Steerable Sheath 
12 Fr  Yes  4FC12  Canada (investigational) 
US (investigational)  
Arctic Front 
Advance® Cardiac 
Cryoablation 
Catheter  No 2AF233  Canada (commercial)  
2AF283  Canada (commercial)  
2AF234  US (investigational)  
2AF284  US (investigational)  
Freezor® MAX 
Cardiac 
Cryoablation 
Catheter  No 209F3  Canada (commercial)  
209F5  Canada (commercial)  
239F3  US (investigational)  
239F5  US (investigational)  6.  Product Description  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinic al Investigation Plan  
Version 1.0,  14JUN2017  Page 28 of 111   
  
6.2. ArcticLine Cryoablation  Catheter  
The ArcticLine Catheter is a sterile, single use, minimally invasive intravascular catheter specifically 
designed for cardiac tissue cryoablation via a linear ablation segment. The ArcticLine Catheter is 
used together with the CryoConsole and related devic es. The Catheter is percutaneously 
advanced to the applicable heart chamber from the femoral access via a transseptal sheath in the 
vasculature. The effective length is 107±2.0 cm. Once the catheter reaches the applicable atrium, it 
is positioned and the a blation segment creates a linear lesion at the targeted location. The 
ArcticLine Catheter is not approved for sale in any  geography.  
The proposed indication for the ArcticLine Catheter evaluated in this Study is as follows:  
 
The ArcticLine Cardiac Cryoabla tion Catheter is indicated for creating endocardial linear lesions, 
subsequent to successful pulmonary vein isolation, during cardiac ablation procedures for treatment of 
patients with persistent atrial fibrillation. The ArcticLine Catheter can also be use d to treat typi[INVESTIGATOR_169213].  
Note: Patients enrolled in the study must have persistent atrial fibrillation. For those subjects who 
also have concomitant typi[INVESTIGATOR_169214] a prophylactic CTI line is 
warranted, the A rcticLine Catheter will be used to create a CTI line for treatment. Patients with 
stand -alone typi[INVESTIGATOR_169215].  
 
6.3. CryoConsole, including Accessories and Catheter  File  
The CryoConsole houses the electronics and software for controlling and recording the ablation 
procedure, stores and controls delivery of liquid refrigerant under high pressure through the co - 
axial umbilical to the catheter, recovers the expanded refriger ant vapor from the catheter under 
vacuum, and disposes of the refrigerant through the hospi[INVESTIGATOR_54364]. The hardware 
controls the safety monitoring systems while the software provides the user interface subject 
information, procedure temperature,  time set point in automatic mode and procedure data 
information.  
 
The sterile coaxial umbilical delivers the Nitrous Oxide (N 2O) gas from the console to the catheter 
and transports refrigerant vapors from the catheter to the console, which is then vented into the 
hospi[INVESTIGATOR_54364].  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinic al Investigation Plan  
Version 1.0,  14JUN2017  Page 29 of 111   
  
The sterile electrical umbilical is an electrical extension cable that transports:  
 
• Temperature feedback from the catheter to the  console  
• Leak detection signals from the catheter to the  console  
• Blood sensor signals from the catheter to the  console  
• Pressure sensor form the catheter to the  console  
 
The catheter file for each respective cryoablation device resides on the CryoConsole. When a 
cat heter is connected to the console, the console searches for the catheter file associated with the 
connected catheter.  The catheter file is read and the parameters from the file are used to 
configure the system accordingly.  
The Arctic Front Advance and Fre ezor MAX catheter files are readily available on the CryoConsole 
at sites as they are market -released devices. Prior to study start at each site, the ArcticLine 
catheter file will be uploaded from a flash drive by [CONTACT_169258].  
 
6.4. FlexCath Advance Steerable Sheath, 12  Fr 
The FlexCath Advance Steerable Sheath, 12 Fr (“sheath”) is a percutaneous introducer fitted with a 
hemostasis valve to allow for introduction, withdrawal and exchange of cat heters and wires while 
providing a barrier preventing air ingress into the valve and minimizing blood loss. A side -port with 
stopcock is integrated into the hemostasis valve to allow continuous drip infusion, injection 
through the center lumen, flushing, a spi[INVESTIGATOR_1516], blood sampling and pressure monitoring. The 
sheath is intended to allow sheath deflection to facilitate catheter positioning. It is supplied sterile 
and packaged together with a dilator.  
The Indications for Use in Canada and the US: The FlexCath  Advance Steerable Sheath is intended 
for percutaneous catheter introduction into the vasculature and into the chambers of the heart. 
The sheath deflection facilitates catheter positioning.  
Investigational Note: As the sheath Instructions For Use for both Canada and the US states it can 
accommodate devices up to 10.5Fr, and the ArcticLine Catheter is 11Fr, the sheath will be used 
investigationally for the purposes of the study.  
 
6.5. Arctic Front Advance Cryoablation Catheter and Related  Devices  
The Arctic Front Advance (“AFA”) Cardiac Cryoablation Catheter is a sterile, single use, minimally 
invasive intravascular balloon catheter specifically designed for tissue cryoablation. The AFA 
Catheter is used together with the CryoConsole and related devices. The AFA Catheter is 
percutaneously advanced to the heart chamber from the femoral access via a transseptal sheath in  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 30 of 111   
  
the vasculature. Once the catheter reaches the left atrium, the ball oon is inflated and the cooling 
segment creates circumferential lesions at the antrum of the targeted pulmonary veins.  
Licensed indication in Canada: The Arctic Front Advance Cardiac Cryoablation Catheter is 
indicated for the treatment of patients with atr ial fibrillation.  
Approved indication in US: The Arctic Front Advance Cardiac Cryoablation Catheters are indicated 
for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation.  
Investigational Note: As the US Arctic Front Advan ce IFU does not include treatment of persistent atrial 
fibrillation, any use of the device at a US study center will be considered investigational.  
The Achieve and Achieve Advance Mappi[INVESTIGATOR_54370] (“Achieve/Achieve Advance mappi[INVESTIGATOR_169216]”) and the Manual  Retraction Kit are used in conjunction with the Arctic Front Advance 
catheter as described below.  
The Achieve/Achieve Advance mappi[INVESTIGATOR_169217] -cardiac electrophysiology diagnostic 
catheter indicated for multiple electrode electrophysiological mappi[INVESTIGATOR_169218], i.e., recording or stimulation only. The Achieve/Ac hieve Advance mappi[INVESTIGATOR_169219].  
The Indications for Use in Canada and the US: The Achieve/Achieve Advance mappi[INVESTIGATOR_169220], i.e. recording or stimulation only. The Achieve/Achieve Adva nce mappi[INVESTIGATOR_169219].  
The Manual Retraction Kit contains one large syringe, one [ADDRESS_197625] the catheter using the normal catheter retraction cycle.  
 
6.6. Freezor MAX Cryoablation  Catheter  
The Freezor MAX Cardiac Cryoablation Catheter (“Freezor MAX”) is a sterile, single use, flexible, 
steerable catheter used to ablate cardiac tissue. It is used together with the CryoConsole and 
related devices. The 8mm tip of the focal Freezor MAX reaches cryoablation temperatures when 
refrigerant is injected from the CryoConsole to the tip of the catheter. The c atheter tip has an 
integrated thermocouple for temperature reading capability. The catheter is introduced into the 
vasculature by [CONTACT_54411].  
Licensed indication in Canada: The Freezor MAX Cardiac Cryoablation Catheter is int ended for use 
in treatment of cardiac arrhythmias.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 31 of 111   
  
Approved indication in US: The Freezor MAX Cardiac Cryoablation Catheters is indicated for use as 
an adjunctive device in the endocardial treatment of paroxysmal atrial fibrillation in conjunction 
with the Arctic Front Advance Cardiac Cryoablation Catheter  for the following uses: gap 
cryoablation to complete electrical isolation of the pulmonary veins, cryoablation of focal trigger 
sites and creation of ablation line between the inferior vena cava and the tricuspid valve.  
Investigational Note: As the US Fre ezor MAX IFU does not include treatment of persistent atrial 
fibrillation, any use of the device at a US study center will be considered investigational.  
 
6.7. Packaging  
In Canada and the US, the ArcticLine Catheter will be labeled as investigational. The sheat h will not 
be labeled as investigational, as this device will be considered investigational upon opening and 
introduction into the vasculature per the CIP. The Achieve/Achieve Advance mappi[INVESTIGATOR_169221], as these device s will be used on label in the Study.  
In Canada, the AFA and Freezor MAX catheters will not be labeled as investigational, as these 
devices will be used on label in the Study.  
In the US, the AFA and Freezor MAX catheters will not be labeled as investigatio nal, as these 
devices will be considered investigational upon opening and introduction into the vasculature per 
the CIP.  
 
6.8. Product Training  Requirements  
Investigators responsible as primary operators for the ablation procedure will be required to 
undergo pr oduct training prior to the site’s first subject treatment. A separate training document 
will overview topi[INVESTIGATOR_169222].  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197626] 
tracking considerations by [CONTACT_169259]:  
• Sheath: Considered inv estigational in both Canada and the US when opened and 
introduced into the  vasculature.  
• AFA: Considered investigational in the US when opened and introduced into  the 
vasculature; non -investigational in  Canada.  
• Freezor MAX: Considered investigational in the  US when opened and introduced into the 
vasculature; non -investigational in  Canada.  
 
The ArcticLine Catheter Files will be stored on flash drives and uploaded by [CONTACT_169260] 
(e.g. Field Clinical Engineers) to the CryoConsoles identified at each study site. The flash drives will 
not be handled directly by [CONTACT_169261]. Once a Catheter File is installed on a site’s 
CryoConsole, Medtronic personnel will affix a label denoting the presence of investigational 
software. See Appendix A  for the example text of the CryoConsole investigational label. Once 
study enrollment is completed, the ArcticLine Catheter File will be uninstalled from the 
CryoConsole by [CONTACT_169260]. Medtronic will manage the device a ccountability for the 
Catheter File and provide each site with a copy of the device disposition log.  
The following products are to be returned to Medtronic by [CONTACT_129583]:  
 
• All ArcticLine Catheters, including expi[INVESTIGATOR_169223]  
• Any AFA or Freezor MAX catheter with a reportable device  deficiency  
• Any  sheath  used  in conjunction  with  an ArcticLine  Catheter  with  a reportable  device 
deficiency  
 
Device disposition logs will be provided to all centers and used for tracking of all investigational 
product throughout the duration of the study, except for the Catheter File device disposition log 
which will be owned by [CONTACT_169262]. The logs  must be maintained and updated when 
product is disposed of or returned to Medtronic.  
 
6.10.  Product  Storage  
ArcticLine Catheters are investigational and will be maintained in locked, secure storage with 
access limited only to approved study staff.  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197627]  Enrollment  
Patients will be screened to ensure they meet all inclusion criteria and none of the exclusion criteria 
prior to study enrollment, as appropriate. IRB/REB/MEC and Medtronic approval of this CIP and t he 
patient Informed Consent Form must be obtained prior to enrolling subjects in the study.  
Enrollment of the subject must occur prior to performing any study procedures. Subjects are 
enrolled at the time the patient Informed Consent Form is signed and dat ed. 
 
7.3. Inclusion Criteria  
• Symptomatic persistent AF, defined as continuous AF that is sustained beyond 7 days and 
documented via consecutive ECG  recordings  
• Age 18 through 80 years  old 
• Failure  or intolerance  of at least  one  Class  I or III antiarrhythmic  drug  
• Subject  is able  and  willing  to consent  to participate  in the  study  and  will  commit  to 
completion of all follow -up requirements  
 
7.4. Exclusion  Criteria  
• Longstanding persistent AF, defined as continuous AF greater than 12 month  duration  
• Left atrial diameter greater than 5.0  cm 
• Acti ve systemic  infection  
• History  of thromboembolic  event  within  the  past  6 months  or evidence  of intracardiac 
thrombus at the time of the  procedure  
• Prior left atrial ablation attempt, with exception  of: 
o Any pulmonary vein isolation attempt to treat AF,  or 
o Successful ablation to treat Wolff -Parkinson White  syndrome  
• History of left atrial  tachycardia  
• History of cardiac ablation within 90 days of planned clinical study  procedure  7.  Selection of Subjects  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 34 of 111   
  
• Planned concom itant ventricular  ablation16 
• Cryoglobulinemia  
• Structural heart disease of clinical significance  including:  
o NYHA Class IV Heart  Failure  
o Diagnosed with NYHA Class III Heart Failure for more than six months at time of the 
study ablation  procedure  
o LVEF less than  35%  
o Any cardiac surgery (e.g. CABG) within 3 months of the ablation  procedure  
o Any mechanical heart valve, prior aortic or tricuspid valve replacement  (e.g. 
valvotomy, valve replacement), or tricuspid valve  repair  
o Severe mitral valve regurgitation or  stenosis  
o Significant congenital anomaly or anatomy unable to accommodate  device  
• Prior surgical maze  procedure  
• Unstable  angina  
• Myocardial infarction within 3  months of the ablation  procedure  
• Presence of primum or secundum atrial septal  defect  
• Anomalous pulmonary venous  return  
• Prior surgery for congenital heart disease, including atrial septal  defect  
• Hypertrophic cardiomyopathy with LV septal wall thickness >1. 5 cm 
• Uncontrolled  hyperthyroidism  
• Thrombocytosis, thrombocytopenia (including history of heparin -induced 
thrombocytopenia)  
• Severe  comorbidity  or poor  general  physical/mental  health  that,  in the  opi[INVESTIGATOR_2339], will not allow the subject to be a good study  candidate  
• History of blood clotting or bleeding  abnormalities  
• Contraindication  to all anticoagulation  (e.g.  novel  oral  anticoagulants,  heparin  or warfarin)  
• Pregnant, nursing or planning to become pregnant during study  duration  
• Enrollment in another clinical trial without prior approval from  Medtronic  
• Presence or use of left atrial appendage closure  device  
• Presence  of or planned  implantation  of a pacemaker,  implantable  cardiac  defibrillator, 
implantable loop recorder or cardiac resynchronization device with permanent lead 
placement  
• Pre -existing hemidiaphragmatic  paralysis  
• Life expectancy less than one  year  
• Known drug or alcohol  dependency  
 
 
[ADDRESS_197628] at the time of the procedure as assessed by [CONTACT_737]. However, the ArcticLine Catheter 
may not be us ed for these purposes.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 35 of 111   
  
• Existing pulmonary vein  stent(s)  
 
Note: For exclusion criteria that cannot be fully assessed in a subject at the time of baseline, but are 
found to be met during the procedure (e.g. left atrial tachycardia, anatomy unable to accommodate 
the device), the subject will be exited from the stud y at that time.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 36 of 111   
  
 
 
8.1. Schedule of  Events  
Data collection requirements are summarized in Table 3 , below.  8.   Study Procedures  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 37 of 111   
  
Table  3: Study Procedures and Data Collection by [CONTACT_169263]-Discharge 
1 week1 
3 mon th2 
6 mon th2 
12 mon th2 
Unscheduled  
Repeat Ab lation 
after Blank ing 
Informed Consent  X         
Inclusion/Exclusion Criteria  X         
Medical History  X         
Physical Exam  X         
AAD & Anticoagulation Medication Review  X  X X X X X X  
Pregnancy Screen3 X         
Arrhythmia Symptom Review  X   X X X X X  
Transthoracic Echocardiogram (TTE)4 X         
Transesophageal Echocardiogram (TEE)  X         
12 Lead ECG  X  X  X X X X  
Procedure Information   X       X 
24 Hr Continuous Monitoring with Holter       X X   
Patient Activated Ambulatory ECG 
Monitor      Monthly and symptomatic 
epi[INVESTIGATOR_169224]:  
1Phone visit and/or office visit with Nurse Coordinator  
2Office visit  
3Female subjects of child bearing potential only  
[ADDRESS_197629]  Consent  
Patient informed consent (IC) is defined as a legally effective documented confirmation of a 
subject’s (or their legally authorized representative) voluntary agreement to participate in a 
particular clinical study after information has been given to the su bject on all aspects of the clinical 
study that are relevant to the subject’s decision to participate. This process includes obtaining a IC 
Form and an Authorization to Use and Disclose Personal Health Information (US only) that has been 
approved by [CONTACT_169264]’s IRB/REB/MEC and signed and dated by [CONTACT_169265]. A subject may only consent after information has been given to the 
subject on all aspects of the clinical investigation that are relevant to the subjec t’s decision to 
participate. Informed consent may be given by [CONTACT_169266] a 
subject is unable to make the decision to participate in a clinical investigation. In such cases, the 
subject shall also be informed about the c linical investigation within his/her ability to understand.  
Prior to enrolling subjects, the IC Form must have been approved by [CONTACT_37330]’s IRB/REB/MEC. 
Each site must also use an Authorization to Use and Disclose Personal Health 
Information/Research Aut horization (US only) or other privacy language as required by [CONTACT_2371]. The IC 
Form must be controlled (i.e. versioned and/or dated) to ensure it is clear which version(s) were 
approved by [CONTACT_1201]/REB/MEC. Any adaptation of the sample IC Form must be reviewed a nd 
approved by [CONTACT_169267]/REB/MEC reviewing the application prior to enrolling subjects.  
The Investigator must notify the subject (or their legally -authorized representative) of any 
significant new findings about the study that become available during the study which are pertinent 
to the safety and well -being of the subject. This could impact a subject’s willingness to participate 
in the study. If relevant, approval may be requested from subjects to confirm their continued 
participation.  
Prior to  initiation of any study -specific procedures, documented informed consent must be 
obtained from the subject (or their legally authorized representative). Likewise, privacy or health 
information protection regulation may require subjects to sign additional forms to authorize 
centers to submit subject information to the study sponsor. The informed consent process must 
be conducted by [CONTACT_079] [INVESTIGATOR_169225], and the IC Form and the 
Authorization to Use and Disclose Personal Health  Information/Research Authorization/other 
privacy language (US only) as required by [CONTACT_169268] (or their legally 
authorized representative) in a language he/she is able to read and understand. The process of 
informed consent must be c onducted without using coercion, undue or improper influence on, or 
inducement of the subject to participate by [CONTACT_169269]. The 
informed consent process shall not waive or appear to waive the subject’s legal rights. The 
lang uage used shall be as non -technical as possible and must be understandable to the subject and 
the impartial witness, where applicable.  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197630] decides to participate in the clinical study, the IC Form and the Authorizat ion to 
Use and Disclose Personal Health Information/Research Authorization/other privacy language (US 
only) as required by [CONTACT_169270] (or their legally 
authorized representative) and either the Investigator or th e Investigator’s authorized designee, 
as required by [CONTACT_1769]. If applicable, witness shall also sign and personally date the consent form 
to attest that the information in the IC Form was accurately explained and clearly understood by 
[CONTACT_423], and th at informed consent was freely given.  
A copy of the IC Form and the Authorization to Use and Disclose Personal Health 
Information/Research Authorization/other privacy language as required by [CONTACT_2371] (US only), signed 
and dated as required by [CONTACT_2371], must be provi ded to the subject.  
If consent is obtained the same day the subject begins participating in study -related procedures, it 
must be documented in the subject’s case history that consent was obtained prior to participation 
in any study related procedures. It i s best practice for the informed consent process to be 
documented in the subject’s case history, regardless of circumstance.  
In the event the subject cannot read and/or write, a witnessed (impartial third party) IC Form will be 
allowed, provided detailed d ocumentation of the process is recorded in the subject’s case history 
and the witness signs and dates the IC Form.  
The original of the signed IC Form and the Authorization to Use and Disclose Personal Health 
Information/Research Authorization/other privacy language (US only) as required by [CONTACT_169271][INVESTIGATOR_307]/clinical chart and/or with the subject’s study  documents and should also be 
available for monitoring and auditing. Any Medtronic Field personnel who support the study 
procedure must be able to review the subject’s signed and dated IC Form and verify its 
completeness prior to proceeding with the proced ure. In the event the Medtronic Field personnel 
identify an IC Form as being incomplete, the study procedure will not be allowed to occur until the 
consent of the subject can be adequately and appropriately obtained.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 40 of 111   
  
8.3. Baseline and Pre -Ablation  Procedure  
The baseline visit can be a standalone visit or can be performed on the same day but prior to the 
cryoablation procedure. The following evaluations will be performed after consent, unless 
previously performed as part of ro utine clinical evaluations within the specified windows:  
Within 6 months prior to consent date:  
 
• Transthoracic echocardiogram (TTE) for the collection of left atrial diameter, left 
ventricular ejection fraction, and mitral valve impairment. A repeat TTE pr ocedure for the 
Study after the consent date is not required if a TTE was performed within 6 months of the 
consent data and all data are  available.  
 
After consent date but prior to procedure:  
 
Note: The time between the consent date and the procedure shoul d not exceed [ADDRESS_197631] inclusion and exclusion criteria to ensure they still 
qualify for the study.  
• Assessment of all factors specified for evaluation under Inclusion Criteria and Exclusion 
Criteria (see Sections  7.3 and 7.4,  respectively).  
o Note:  After  required  study  testing,  if a subject  no longer  meets  the  inclusion  criteria 
or now  meets  exclusion  criteria,  the  subject  will  be exited  from  the  study.  
• Demographics  
• Medical  history  
• Physical  examination  
• Pregnancy screen (female subjects of child bearing potential  only)  
• 12 lead ECG  
• Record rhythm and class I and III AAD and anticoagulation  medications  
• Transesophageal Echocardiogram  (TEE):  
o TEE will be performed in all subjects within [ADDRESS_197632]  will  not  proceed  with  the  study  ablation  procedure  and  will  be exited  from 
the study if presence of atrial thrombus is  identified.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 41 of 111   
  
8.4. Procedure  
The Investigator is to perform the procedure according to the procedural steps in this CIP and the 
applicable Instructions for U se for all devices (except for investigational uses as described in this 
CIP). Current recommendations for anticoagulation are found in the 2017 
HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical 
Ablation of Atrial Fibrillation2 and 2014 Focused Update on the Canadian Cardiovascular Society 
Guidelines for the Management of Atrial Fibrillation.17 
 
8.4.1.  High Level Procedure  Overview:  
Appropriate sedation and venous access should be attained per the Invest igator’s standard 
practice according to their institution’s pre -established procedures/guidelines at the time of the 
procedure. Investigator may choose compatible guidewires and mappi[INVESTIGATOR_169226]. The FlexCath Advance 12Fr sheath must b e used. Deploy diagnostic catheters and 
perform transseptal puncture.  
Perform a baseline voltage map of the left atrium using a 3D mappi[INVESTIGATOR_16816] (e.g. NavX, 
Rhythmia). Recommended settings for minimum voltage in this study is 0.2mV.  
Perform baseline mappi[INVESTIGATOR_169227] a 
circular mappi[INVESTIGATOR_169228] (e.g. Achieve Advance) to determine if PVI is required. If yes, perform the 
pulmonary vein isolation procedure using Arctic Front Adva nce Catheter as per Section 8.4.[ADDRESS_197633] with ArcticLine ablation, p erform 
the following required linear ablations using the ArcticLine Catheter as per Section 8.4.6 : 
• Left atrial roof  line  
• Left atrial posterior wall  line  
 
Note: An example where the investigator may choose not to move forward with ArcticLine ablation 
and instead, exit the subject from the study, is when a subject has previously undergone PVI and 
has minimal pulmonary vein reconnection which, in the opi[INVESTIGATOR_1649] o f the investigator, only requires 
touch -up ablation.  
 
 
 
 
 
 
17 Verma A, et al. 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial 
Fibrillation. Canadian Journal of Cardiology. 30 (2014) 1114 -1130.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 42 of 111   
  
At the investigator’s discretion, perform optional linear ablations at the following anatomic targets  
using the Arct icLine Catheter:  
 
• Mitral isthmus (see Section  8.4.7 ) 
• CTI (see Section  8.4.8 ) 
 
At the investigator’s discretion, use pacing maneuvers to determine the immediate effect of the 
ArcticLine ablation(s). Note: Direct Current (DCCV) or pharmacological cardioversion may be 
considered at any point during the procedure when restoration of SR will assist in assessing the 
effectiveness of cryoablations or deemed necessary for the benefit of the patient.  
Repeat ArcticLine ablation(s), as necessary to achieve conduction block, as described in Sections 
8.4.[ADDRESS_197634] is in Sinus Rhythm.  
Notes:  
 
• Reference ArcticLine Technical Guidance for recommendations on pacing maneuvers and 
3D mappi[INVESTIGATOR_169229].  
• If Investigator  is unable  to successfully  complete  a lesion  with  the  ArcticLine  Catheter  after 
a minimum of four (4) ArcticLine ablation applications, they may cross over to another FDA 
approved catheter.  This will be considered an ArcticLine treatment  failure.  
• Temperatures of –80⁰C ar e expected with use of the ArcticLine  Catheter.  
• Methods  used  to assess  for conduction  block  must  be documented  and  reported.  
• Copi[INVESTIGATOR_169230].  
 
8.4.2.  Esophageal Visualization and Temperature  Monitoring  
Ensure an esophageal temperature monitor is used for each cryoablation application (Arctic Front 
Advance if applicable and ArcticLine). Cease cryoablation if the temperature reaches ≤25°C2. Use 
of proton pump inhibitors (PPI) is recommended in all ArcticLine Catheter -treated subjects for at 
least [ADDRESS_197635] systemically anticoagulated with warfarin or novel oral anticoagulants 
(NOACs) does not alter the need for intravenous heparin to maintain a therapeutic ACT during the 
procedure. Admi nistration of protamine following ablation to reverse heparin should be 
considered.  
 
8.4.4.  Diaphragm  Movement  
Continuous pacing of the applicable phrenic nerve must be performed for each anatomic target as 
noted in Table 4.  Additio nal methods of phrenic nerve monitoring are recommended.  
 
Table 4:  Required Phrenic Nerve Pacing  
 
Anatomic Target  Right Phrenic Nerve 
Pacing  Left Phrenic Nerve 
Pacing  
Right -sided pulmonary veins (if applicable)  Required  Not applicable (N/A)  
Left -sided pulmonary veins (if applicable)  Optional  Optional  
Roof  Required  N/A  
Posterior wall  Required  N/A  
Mitral isthmus (if applicable)  N/A  Required  
Cavotricuspid isthmus (if applicable)  Required  N/A  
 
8.4.5.  Pulm onary Vein Cryoablation with Arctic Front Advance  Catheter  
Subjects will be evaluated to determine the need for PVI. If the need is confirmed based on 
intracardiac electrogram recordings, every effort consistent with subject welfare should be made 
to treat  all PVs or their anomalous equivalents where electrical activity is noted.  
Subjects in the Study who require pulmonary vein isolation are to be treated as follows:  
 
• As stated in Section 8.4,  perform a baseline voltage map of  the  left atrium using a 3D 
mappi[INVESTIGATOR_169231].  
• Ablate the pulmonary veins using the Arctic Front Advance Catheter according to the  IFU.  
• Each pulmonary vein must be assessed for entrance block to demonstrate  electrical 
isolation. Optionally, pulmonary vein ass essment for exit block may be  performed.  
• Perform repeat voltage mappi[INVESTIGATOR_169232] a 3D mappi[INVESTIGATOR_169231].  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 44 of 111   
  
Notes:  
 
• Upon the Investigator’s assessment of procedure completion, Isoproterenol and/or 
adenosine may be used to further assess pulmonary vein  isolation.  
• Freezor MAX should be used for any gap completion or other FDA approved ablation 
catheter.  In the event Freezor MAX is not used for gap completion, the subject will be 
exited from the  study.  
 
8.4.6.  Linear Cryoablation with ArcticLine Catheter: Roof and Posterior  Wall  
Once confirmation all pulmonary veins have been isolated and the investigator determines the 
subject should move forward with ArcticLine ablation, perform the following steps:  
Withdraw and remove the Arctic Front Advance catheter through the FlexCath  Advance sheath.  
 
Insert and advance ArcticLine Catheter into the left atrium via the FlexCath Advance sheath and 
position as follows:  
• Roof: Position the ArcticLine Catheter between the right and left superior pulmonary  veins.  
• Posterior wall: Position Arct icLine Catheter between the inferior pulmonary  veins.  
 
Repeat the following steps for both the roof and posterior wall locations:  
 
• Assess the positioning and contact [CONTACT_169272], ultrasound imaging, or  other 
visualization technique.  Reposition as  needed.  
• Perform the cryoablation. Cryoapplications of three (3) minutes is recommended for the 
roof and posterior wall targets in the l eft atrium.  
• At the investigators discretion, use pacing maneuvers to determine the immediate  effect 
of the ArcticLine  ablation(s).  
• Note: It is the investigator’s discretion to assess necessity of additional freezes to 
complete the desired ablation  line.  
 
Once the roof line and posterior wall lines are completed, assess the posterior wall for isolation 
using pacing maneuvers and/or 3D mappi[INVESTIGATOR_007].  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 45 of 111   
  
If no further ArcticLine ablation(s) in the left atrium will be performed:  
 
• Repeat voltage mappi[INVESTIGATOR_007] o f the left atrium using a 3D mappi[INVESTIGATOR_169233] a minimum [ADDRESS_197636] ArcticLine ablation for each respective anatomy  target.  
• Use of [ADDRESS_197637] is in Sinus  Rhythm.  
 
Notes:  
 
• Upon the Investigator’s assessment of procedure completion, Isoproterenol  and/or  
adenosine may be used to further assess pulmonary vein conduction.  
• Freezor MAX may be used at the investigators discretion to touch up gaps in conduction if 
complete  pulmonary  vein  isolation  was  not  achieved  with  the  Arctic  Front  Advance.  
 
8.4.7.  Linear Cryoablation with ArcticLine Catheter: Mitral  Isthmus  
If th e investigator chooses to perform a mitral isthmus line ablation, perform the following steps:  
 
Advance the ArcticLine Catheter to the mitral isthmus by [CONTACT_169273].  
Assess the positioning and contact [CONTACT_169272], ultrasound imaging, or other visualization 
technique.  Reposition as needed.  
Perform the cryoablation. Cryoapplications of three (3) minutes is recommended at the mitral 
isthmus.  
• Note: It is the investigator’s discretion to assess necessity of additional freezes to 
complete the desired ablation  line.  
 
Assess for bi -directional conduction block across the mitral isthmus, while subject is in sinus 
rhythm, using pacing maneuvers and/or 3D mappi[INVESTIGATOR_169234].  
 
• Note: Direct Current (DCCV) or pharmacological cardioversion should be performe d prior 
to assessing patient for conduction  block.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 46 of 111   
  
If no further ArcticLine ablations in the left atrium will be performed:  
 
• Reconfirm bi -directional conduction block at the mitral isthmus following a [ADDRESS_197638] ArcticLine  ablation.  
• Repeat voltage mappi[INVESTIGATOR_169232] a 3D mappi[INVESTIGATOR_169233] a minimum 30 - 
minute wait time for each respective ArcticLine  lesion.  
• Use of [ADDRESS_197639] is in Sinus  Rhythm.  
• Local Activation Time (LAT) Mappi[INVESTIGATOR_169235] a 30- 
minute wait may be  considered.  
 
Notes:  
 
• Upon the Inv estigator’s assessment of procedure completion, Isoproterenol and/or 
adenosine may be  used.  
• Freezor MAX should be used if gap completion is  required.  
 
8.4.8.  Linear Cryoablation with ArcticLine Catheter: Cavotricuspid  Isthmus  
If the investigator chooses to perfor m a CTI line ablation, perform the following steps:  
 
Advance the ArcticLine Catheter to the CTI by [CONTACT_169274].  
Assess the positioning and contact [CONTACT_169272], ultrasound imaging, or other technique. 
Reposition as needed.  
Perform the cryoablation. Cryoapplications of four (4) minutes is recommended at the CTI.  
 
• Note:  It is the  investigator’s  discretion  to assess  necessity  of additional  freezes  to 
complete the desired ablation line.  
 
Assess the CTI line for bi -directional conduction block using pacing maneuvers and/or 3D mappi[INVESTIGATOR_169236] a 30 -minute wait.  
 
Notes:  
• Upon the Investigator’s assessment of proced ure completion, Isoproterenol  and/or  
adenosine may be used.  
• Note: Freezor MAX should be used if gap completion is  required.  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197640] Current (DCCV) or pharmacological cardioversion may be considered at any point during the 
procedure when restoration of SR will assist in assessing the effectiveness of cryoablations or 
deemed necessary for the benefit of the patient. Electrical or pharmacological cardioversion to 
sinus rhythm must be attempted at the conclusion of the procedure if sinus rhythm was not 
restored.  
 
8.4.10.  Role of Medtronic Personnel at Study  Procedure  
Medtronic personnel will collect procedural data from the CryoConsole post -procedure via data 
download. It is the responsibility of the study center to ensure the subject is identified via subject 
ID number when entered into the system to prevent the distribution of personally identifiable 
information.  
 
8.5. Hospi[INVESTIGATOR_169237] s hortly before hospi[INVESTIGATOR_2345], the following will be performed and collected:  
 
• Adverse event  assessment  
• Review  medications  
• 12 lead ECG  
• Review study requirements with the subject to help ensure compliance with follow -up 
procedures  
 
Systemic anticoagulation with warfarin or a direct thrombin or Factor Xa inhibitor is recommended 
for at least two months following the AF ablation procedure; however, the anticoagulation 
treatment will be at the Investigator’s discretion according to esta blished guidelines. Decisions 
regarding the continuation of systemic anticoagulation agents more than two months following 
ablation should be based on the subject’s risk factors for stroke and not on the presence of AF.  
Use of proton pump inhibitors (PPI) is recommended in all ArcticLine Catheter -treated subjects for 
at least [ADDRESS_197641] -procedure blanking period.  
Information regarding medications prescribed for anticoagulation, proton pump inhibitors, or to 
treat atrial arrh ythmias (including adenosine and isoproterenol use during the ablation procedure), 
will be collected from subject enrollment through study exit, including the medication name, dose 
and frequency.  
 
8.6.1.  Class I and III antiarrhythmic medication use after the [ADDRESS_197642] -procedure 
blanking  period  
• Subjects may re -initiate, at any point during follow -up, a Class I or III antiarrhythmic 
medication that failed or was not tolerated prior to the ablation procedure at the same  or 
lower  dose.  
• Initiation  of a new  Class  I or III antiarrhythmic  medication  or a dose  increase  after  the 
blanking period will be considered a treatment  failure.  
• All medications are permitted in the study except for investigational drugs that may 
confound the study  results.  
 
8.7. Permissible Repeat  Cryoablation  
Repeat ablation, following the same procedure described in Section 8, is allowe d one time within 
the [ADDRESS_197643] -procedure blanking period.  
• Durability of all lesions, including pulmonary vein and linear lesions, will be assessed for gaps 
prior to re -ablating target  locations.  
• Ablation of linear lesions, outside of those described in Section 8, will be considered a 
treatment  failure.  
• Linear ablation using RF in the left or right atria will be considered a treatment failure with 
the  exception  of sub jects  who  did not  undergo  CTI  ablation  with  the  ArcticLine  Catheter  in 
their index study  procedure.  
• Pulmonary vein ablation touch -up using RF will be considered a treatment  failure.  
 
Repeat ablation procedures will be documented on an electronic case repor t form (eCRF). The 
subject’s procedures and follow -up windows will continue based on the index ArcticLine Catheter 
ablation procedure date.  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197644] be accompanied by a dev iation. 
Follow -up visit windows are listed in Table 5  and are based on days after the index ArcticLine 
Catheter ablation procedure.  
 
Table 5:  Follow -up Schedule  
 
 
Occurrence/ 
Visit  Window  
(Calculated days after the ablation 
procedure)  
Window Start  Window End  
Enrollment/Baseline1 -30 days  Day 0  
Index ArcticLine 
Procedure  Day 0  Day 0  
1 week phone or office  7 days  14 days  
3 month office  91 days  105 days  
6 month office  165 days  179 days  
12 month office  365 days  379 days  
1Note: If the time between the consent date and the procedure exceeds [ADDRESS_197645] inclusion and exclusion criteria to 
ensure they still qualify for the study.  
 
The following information is required to be collected at the follow -up visits:  
 
8.8.1.  One Week Phone or Office  Visit  
• Review  medications  
• Adverse event  assessment  
• Review symptoms suggestive of recurrent  AF/AT/AFL  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 50 of 111   
  
8.8.2.  Three Month Office  Visit  
• Review  medications  
• Adverse event  assessment  
• Review symptoms suggestive of recurrent  AF/AT/AFL  
• 12 lead ECG  
• Provide the subject with patient activated ambulatory monitoring equipment and provide 
instructions for monthly and symptomatic  transmissions  
 
8.8.3.  Six Month Office  Visit  
• Review  medications  
• Adverse event  assessment  
• Review symptoms suggestive of recurrent  AF/AT/ AFL  
• 12 lead ECG  
• 24-hour continuous monitoring with  Holter  
• Remind subject of instructions on patient activated ambulatory monitoring equipment for 
monthly and symptomatic  transmissions  
 
8.8.4.  Twelve Month Office  Visit  
• Review  medications  
• Adverse event  assessment  
• Review symptoms suggestive of recurrent  AF/AT/AFL  
• 12 lead E CG  
• 24-hour continuous monitoring with  Holter  
• Collect or ensure return of ambulatory monitoring  equipment  
 
8.8.5.  Unscheduled Office  Visits  
An unscheduled visit is defined as any unplanned cardiovascular -related office visit or early study 
exit at the study center that occurs between CIP required visits. If the subject exits the study early, 
an unscheduled office visit should occur. The follow ing information is required to be collected at 
unscheduled follow -up visits:  
• Review  medications  
• Adverse event  assessment  
• Review symptoms suggestive of recurrent  AF/AT/AFL  
• [ADDRESS_197646] data using an electronic da ta management system for clinical studies. 
Centers will enter data onto case report forms (CRFs) within the electronic database. The 
Holter/Patient Ambulatory Monitoring/[ADDRESS_197647]’s rights, safety and well -being, or the scienti fic integrity of the study, prior approval 
from IRB/REB/MEC may also be required, depending on local requirement. Prior approval is not 
required when a deviation is necessary to protect the safety, rights or well -being of a subject in an 
emergency or in un foreseen situations beyond the Investigator’s control (e.g. subject failure to 
attend scheduled follow -up visits, inadvertent loss of data due to computer malfunction, inability 
to perform required procedures due to subject illness). Subjects’ failure to s ubmit ambulatory 
monitoring transmissions per the CIP does not require a deviation to be reported. Ambulatory 
monitoring  transmission  compliance  will  be tracked  by [CONTACT_169275].  
For medically justifiable conditions which preempt a s ubject’s ability to complete a study -required 
procedure, it may be permitted to report only one deviation which will apply to all visits going 
forward. This may also apply for other unforeseen situations (e.g. the subject permanently refuses 
to complete a study required procedure and the data will not contribute to the primary endpoint 
analysis). However, prior approval from Medtronic is required for such situations.  
All study deviations must be reported on the eCRF regardless of whether medically justifiab le, pre - 
approved by [CONTACT_13735], an inadvertent occurrence, or taken to protect the subject in an 
emergency. The deviation description must be recorded with an explanation for the deviation.  
In the event the deviation involves a failure to obtain a subject’ s consent, or is made to protect the 
life or physical well -being of a subject in an emergency, the deviation must be reported to the 
IRB/REB/MEC as well as Medtronic within five (5) working days. Reporting of all other study 
deviations should comply with I RB/REB/MEC policies and/or local laws and must be reported to 
Medtronic as soon as possible upon the center becoming aware of the deviation. Reporting of 
deviations must comply with IRB/MEC policies, local laws, and/or regulatory agency requirements.  
Medtr onic is responsible for analyzing deviations, assessing their significance, and identifying any 
additional corrective and/or preventive actions (e.g. CIP amendment, conduct additional training, 
terminate the investigation). Repetitive or serious Investigat or compliance issues may result in 
initiation of a corrective action plan with the Investigator and center, and in some cases, 
necessitate suspending enrollment until the problem is resolved or ultimately terminating the 
Investigator's participation in the  study. Medtronic will provide center -specific reports to 
Investigators summarizing information on deviations that occurred at the investigational center on 
a periodic basis.  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197648]’s 
medical record. In addition, centers shall follow the regulations set forth by [CONTACT_11577]/REB/MEC.  
It is recommended that Investigators follow the subject until all device and/or procedure -related 
adverse events are recovered / resolved or unresolved with no further actions planned. Following 
completion of the [ADDRESS_197649]’s exit will be used for analysis.  
Reasons for early study exit include:  
 
• Subject lost to  follow -up 
• Subject did not meet inc lusion/exclusion criteria after consent and did not undergo an 
ablation  procedure  
• ArcticLine Catheter was not used during the subject’s ablation  procedure  
• Subject did not provide consent or data  use protection authorization  
• Subject chooses to withdraw (e.g ., consent withdrawal, relocation to another geographic 
location)  
• Investigator  deems  withdrawal  necessary  (e.g.,  medically  justified,  inclusion/exclusion 
criteria not met, failure of subject to maintain adequate study  compliance)  
• The sponsor decides the study will be closed or a particular center will be  closed.  
 
In the case that the subject is determined to be lost to follow -up, details  of a minimum of two 
attempts  and  the  method  of attempt  (e.g.,  one  letter  and  one  phone  record  or two  letters)  to 
contact [CONTACT_169276].  
An unscheduled office visit should be attempted if the subject exits the study outside of a 
scheduled fo llow -up visit. Subjects treated with the ArcticLine Catheter who exit from the study 
should continue to be followed by [CONTACT_169277] -up of any potential adverse 
events at the recommended interval of [ADDRESS_197650] may 
be enrolled to achieve the target sample size of N=[ADDRESS_197651] be continuously monitored, 
assessed and documented by [CONTACT_737]. Possible additional risks for partic ipating in the 
study include the following (although others are possible) and are further defined in Appendix C : 
• Access site complications (e.g. 
bruising,  ecchymosis)  
• Anemia  
• Anxiety  
• Arrhythmia (e.g. atrial flut ter, 
bradycardia, heart block,  tachycardia)  
• Back pain  
• Bleeding, possibly  requiring 
transfusion  
• Bronchitis  
• Cardiac  tamponade  
• Cardiopulmonary  arrest  
• Catheter entrapment in cardiac 
structures requiring  intervention  
• Cerebral vascular  accident  
• Chest  discomfort/pain/pressure  
• Cold  feeling  
• Coronary artery  spasm  
• Cough  
• Death  
• Diarrhea  • Dizziness  
• Embolism  
• Esophageal damage (including 
atrioesophageal  fistula)  
• Fatigue  
• Fever  
• Headache  
• Hemoptysis  
• Hypotension/hypertension  
• Infection (e.g.  sepsis)  
• Lightheadedness  
• Myocardial  infarction  
• Nausea/vomiting  
• Perforation  
• Pericardial  effusion  
• Pericarditis  
• Phrenic nerve  injury  
• Pleural  effusion  
• Pneumonia  
• Pneumothorax  
• Pulmonary vein  stenosis  9.   Risks and Benefits  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 55 of 111   
  
• Pseudoaneurysm  
• Pulmonary  edema  
• Pulmonary vein  stenosis  
• Shivering  
• Shortness of  breath  
• Sore  throat  
• Transient ischemic  attack  
9.2. Potential  Benefits  • Urinary tract  infection  
• Vagal nerve injury (e.g.  gastroparesis)  
• Valve damage with  potential 
regurgitation  
• Vasovagal  reaction  
• Visual  change  
The ArcticLine Catheter, designed to create linear cardiac lesions which interrupt errant electrical 
signals, may reduce or eliminate persistent atrial fibrillation in subjects with confirmed pulmonary 
vein isolation; however, some subjects may not receive this benefit. Using ArcticLine to create 
linear lesions may result in shorter procedure times, and contain fewer gaps, than lines created 
with traditional point -by-point technology resulting in the possibility of less fluoroscopy a nd 
anesthesia exposure to subjects. Additionally, the ArcticLine Catheter may be an improved 
technology over RF ablation in creating lesions that are not only continuous but transmural and 
durable.  
Clinical benefit has not been demonstrated as this study i s the first human use of the ArcticLine 
Catheter.  The  information  gained  from  the  study  could  result  in improved  management  of atrial 
fibrillation.  
 
9.3. Risk -Benefit  Rationale  
The cohort of subjects for inclusion in the study is symptomatic as a result of their persistent atrial 
fibrillation and the failure of Class I or III antiarrhythmic drug therapy. Alternatives to creation of 
linear lesions with the ArcticLine Catheter in t his cohort includes pulmonary vein isolation alone or 
point -by-point linear ablation using RF technology. Investigation into the former with AFA is 
currently ongoing; the latter has not proven efficacy in this population, possibly due to the lack of 
durabl e transmural lesions15 and/or understanding of the underlying substrate18. 
Cryoablation therapy offers the opportunity to reduce the epi[INVESTIGATOR_169238]’s risk of stroke and symptoms. The use of the ArcticLine Catheter, a 
technology that can create a linear lesion with fewer applicatio ns, may reduce the potential for 
gaps through creation of a contiguous line. This may prevent recurrence of atrial fibrillation and 
typi[INVESTIGATOR_169239]/atrial flutter.  
 
 
 
18 Zakeri, et al. The burden of proof:  The current state of atrial fibrillation prevention and treatment trials. Heart 
Rhythm. 2017;14:[ADDRESS_197652] development 
activities for the ArcticLin e Catheter, including an eventual pi[INVESTIGATOR_2397]; the goal of which is to 
confirm meaningful therapeutic benefit of the ArcticLine Catheter to create linear lesions. After 
careful review of the risks and benefits, the benefits are found to outweigh the risk s and justify this 
investigation of the ArcticLine Catheter in this underserved population.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 57 of 111   
  
 
 
10.1.  Definitions/Classifications  
Timely, accurate, and complete reporting and analysis of safety information for clinical studies are 
crucial for the protection of subjects. Reporting and analysis of safety data are mandated  by 
[CONTACT_128631]. Medtronic has established procedures in conformity with 
worldwide regulatory requirements to ensure appropriate reporting of safety information. The 
study is conducted in accordance with these procedures and regulation s. 
Since the safety reporting requirements and classification systems vary for each regulatory 
agency, requirements from all participating geographies are taken into account for the collection 
and reporting of safety information.  
 
10.2.  Adverse Event and Device Deficiency  Definitions  
Table 6:  Adverse Event and Device Deficiency Definitions  
 
General  
Adverse Event (AE)  Any untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal 
laboratory findings) in subjects, users or other persons, 
whether or not related to the investigational medical device  
 
NOTE 1: This definition in cludes events related to the 
investigational medical device or the comparator.  
NOTE 2: This definition includes events related to the 
procedures involved.  
NOTE 3: For users or other persons, this definition is 
restricted to events related to investigationa l medical 
devices.  
(ISO [ZIP_CODE]:2011, 3.2)  
Adverse Device Effect (ADE)  Adverse event related to the use of an investigational medical 
device  
 
NOTE 1: This definition includes adverse events resulting 
from insufficient or inadequate instructions for use, 
deployment, implantation, installation, or operation, or any 
malfunction of the investigational medical device.  
NOTE 2: This definition includes  any event resulting from an 
error use or from intentional misuse of the investigational 
medical device. (ISO [ZIP_CODE]:2011, 3.1)  10.  Adverse Events and Device  Deficiencies  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 58 of 111   
  
Device Deficiency (DD)  Inadequacy of a medical device with respect to its identity, 
quality, durability, reliability, safety or performance.  
 
NOTE: Device deficiencies include malfunctions, use errors 
and inadequate labeling (ISO [ZIP_CODE]:2011, 3.15)  
Relatedness  
Procedure related  An Adverse Event directly related to any portion of the 
procedure.  
System related  An Adverse Event that results from the presence or 
performance (intended or otherwise) of the system (including 
the ArcticLine Catheter, CryoConsole, Arctic Front Advance, 
Freezor MAX, FlexCath Advance Sheath, Achieve Mappi[INVESTIGATOR_169240], Manual Retraction Ki t) 
Cardiovascular related  An Adverse Event relating to the heart and the blood vessels 
or the circulation.  
Not Related  Relationship to the device or procedures can be excluded 
when:  
• The event is not a known side effect of the 
product category the device belongs to or of 
similar devices and  procedures;  
• The event has no temporal relationship with the 
use of the device or the  procedures;  
• The serious event does not follow a known 
response pattern to the medical device (if  the 
response pattern is previously known) and is 
biologically  implausible;  
• The discontinuation of medical device 
application or the reduction of the level of 
activation/ex posure – when clinically feasible – 
and reintroduction of its use (or increase of the 
level of activation/exposure) do not impact  the 
serious  event;  
• The event involves a body -site or an organ not 
expected to be affected by [CONTACT_10398];  
• The serious event can be attributed to  another 
cause (e.g., an underlying or concurrent 
illness/clinical condition, an effect of another 
device, drug, treatm ent, or other risk  factors);  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 59 of 111   
  
 • The event does not depend on a false result 
given by [CONTACT_132621]  (when 
applicable);  
• Harms to the subject are not clearly due to  use 
error;  
• In order to establish the non -relatedness, not all 
the criteria listed above might be met at the 
same time, depending on the type of 
device/procedures and the  event.  
Unlikely  The relationship with the use of the device seems not 
relevant and/or the event can be reasonably explained by 
[CONTACT_5748], but additional information may be obtained.  
Possible  The relationship with the use of the investigational device is 
weak but cann ot be ruled out completely. Alternative causes 
are also possible (e.g. an underlying or concurrent illness/ 
clinical condition or/and an effect of another device, drug or 
treatment). Cases were relatedness cannot be assessed or 
no information has been obta ined should also be classified as 
possible.  
Probable  The relationship with the use of the investigational device 
seems relevant and/or the event cannot reasonably 
explained by [CONTACT_5748], but additional information may 
be obtained.  
Causal Relationship  The event is associated with the device or study procedures 
beyond reasonable doubt when:  
▪ The event is a known side effect of the  product 
category the device belongs to or of similar 
devices and  procedures;  
▪ The event has a temporal relationship  with 
device  use/application or  procedures;  
▪ The event involves a body -site or organ that the 
device or procedures are applied to or the 
device or procedures have an effect  on;  
▪ The serious event follows a known response 
pattern to the medical device (if the  response 
pattern is previously  known);  
▪ The discontinuation of medical device 
application (or reduction of the level of 
activation/exposure) and reintroduction of  its 
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 60 of 111   
  
 use (or increase of the level of 
activation/exposure) impact on the serious 
event (when clinically feasible);  
▪ Other possible causes (e.g., an underlying or 
concurrent illness/clinical condition or/and  an 
effect of another device, drug, or treatment) 
have b een adequately ruled  out;  
▪ Harm to the subject is due to error in  use;  
▪ The event depends on a false result given by [CONTACT_169278] (when  applicable);  
▪ In order to establish the relatedness, not all  the 
criteria listed above might be met at the same 
time, depending on the type of 
device/procedures and the serious  event.  
Seriousness  
Serious Adverse Event (SAE)  Adverse event that  
a) led to  death,  
b) led to serious deterioration in the health of the  subject, 
that either resulted  in: 
1) a life -threatening illness or injury,  or 
2) a permanent impairment of a body structure or a  body 
function,  or 
3) in-patient or prolonged hospi[INVESTIGATOR_059] (>24 hours),  or 
4) medical or surgical intervention to prevent life - 
threatening illness or injury or permanent impairment to a 
body structure or a body  function,  
c) led to fetal distress, fetal death or a  congenital 
abnor mality or birth  defect  
 
NOTE 1: Planned hospi[INVESTIGATOR_272] a pre -existing condition, 
or a procedure required by [CONTACT_10396], without serious 
deterioration in health, is not considered a serious adverse 
event.  
(ISO [ZIP_CODE]:2011, 3.37)  
Serious Adverse Device Effect 
(SADE)  Adverse device effect that has resulted in any of the 
consequences characteristic of a serious adverse event. 
(ISO [ZIP_CODE]:2011, 3.36)  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197653] 
(UADE)  Any serious adverse effect on health or safety or any life - 
threatening problem or death caused  by, or associated with, 
an (investigational) device, if that effect, problem, or death 
was not previously identified in nature, severity, or degree of 
incidence in the CIP or applicable (including a supplementary 
plan or application), or any other unantic ipated serious 
problem associated with a device that relates to the rights, 
safety, or welfare of subjects. (21 CFR 812.3(s))  
Unanticipated Serious Adverse 
Device Effect ([LOCATION_003]DE)  Serious adverse device effect which by [CONTACT_5942], incidence, 
severity or outcome has not been identified in the current 
version of the risk analysis report.  
NOTE: Anticipated serious adverse device effect (ASADE) is 
an effect which by [CONTACT_5942], incidenc e, severity or outcome 
has been identified in the risk analysis report. (ISO 
[ZIP_CODE]:2011 3.42)  
Other  
Unavoidable Adverse Event  An Adverse Event inherent to a surgical procedure that is 
expected to occur in all subjects for a projected duration 
according to the Investigator’s opi[INVESTIGATOR_1649], including, but not 
limited to those provided below. These are not reportable 
AEs unless they occur  after or last longer than the timeframe 
specified. If any other events below are classified as serious 
they must be reported as an adverse event.  
  
 
Event Description  Timeframe 
(hours) from 
the Surgical 
Procedure   
Anesthesia related nausea / vomiting  24 
Low -grade fever (<100°F or 37.8°C)  48 
Mild to moderate bruising / ecchymosis in 
groin area / groin pain  168  
Sleep problems (insomnia)  [ADDRESS_197654]’s participation in the study.  
 
Reporting of these events to Medtronic will occur on an AE eCRF, including a description of AE, 
date of onset of AE, date of awareness of center, treatment, resolution, assessment of both the 
seriousness and the relatedness to the investigational device. Each AE must be recorded on a 
separate AE eCRF.  Exceptions include:  
• Documente d pre -existing  conditions  are  not  considered  AEs  unless  the  nature  or severity 
of the condition has worsened. Additionally, arrhythmia epi[INVESTIGATOR_169241].  
• Unavoidable Adverse Events, listed in Table 6: Adv erse Event and Device Deficiency  
Definitions  need not be reported unless the adverse event worsens or is present outside 
the stated timeframe after the ablation  procedure.  
• Cardioversions  (DC  or Drug)  for recurrent  symptomatic  atrial  fibrillation  and  other  atrial 
arrhythmias are not considered serious adverse  events  
 
Where the definition indicates “device”, it refers to any device used in the study. This might be the 
catheter, or any other component of the system under investig ation, or any market -released 
component of the system.  
For any changes in status of a previously reported adverse event (i.e. change in actions taken, 
change in outcome, change in relatedness), an update to the original AE must be provided. All 
adverse events must be followed until the adverse event has been r esolved, the subject exits the 
study or until study closure, whichever occurs first.  
At the time of study exit, all collected AEs with an outcome of “not recovered/not resolved”, 
“recovering/resolving” or “unknown” must be reviewed and updates provided as applicable.  
All reported adverse events will be reviewed by a Medtronic representativ e. AEs will be classified 
according to the definitions provided.  
Upon receipt of adverse events at Medtronic, a Medtronic representative will review the adverse 
event for completeness and accuracy and when necessary will request clarification and/or 
additi onal information from the Investigator. Medtronic will utilize MedDRA, the Medical Dictionary 
for Regulatory Activities, to assign a MedDRA term for each adverse event based on the 
information provided by [CONTACT_737].  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197655] of required Investigator and Medtronic reporting 
requirements and timeframes. It is the respons ibility of the Investigator to abide by [CONTACT_169279]/MEC responsible for oversight of the study.  
For a list of Foreseeable Adverse Event List (FAL), refer to Appendix C . This  is a list of adverse 
events related to the ArcticLine Catheter or procedure that may be experienced by [CONTACT_1766]. This 
list may help to assess if an adverse event is unexpected in nature. Additionally, refer to Appendix  
D, for expanded definitions on a subset of adverse events as they relate to endpoint assessment.  
For emergency contact [CONTACT_169280] a SAE, contact a clinical study representative immediately (refer 
to the study sponsor per the spon sor contact [CONTACT_3031]).  
Adverse Events and Deaths will be classified according to the standard definitions as outlined in 
Table 8.  
All subject deaths must be reported by [CONTACT_169281] F (AE 
with outcome of fatal) as soon as possible after the Investigator first learns of the death. There 
should be one AE with the outcome of fatal.  
A copy of the death certificate, if available, and allowed by [CONTACT_54443]/local law, should be sent to the 
Medtro nic clinical study team. When a death occurs in a hospi[INVESTIGATOR_307], a copy of the death summary 
report and all relevant hospi[INVESTIGATOR_54380], if 
available. If an autopsy is conducted, the autopsy report should also b e sent to the Medtronic 
clinical study team if available and allowed by [CONTACT_54443]/local law. When the death occurs at a remote 
center, it is the investigative center’s responsibility to attempt retrieval of information about the 
death. In summary, the followin g data will be collected:  
• Date of  death  
• Detailed description of  death  
• Cause of  death  
• Relatedness to device and/or  procedure  
• Death  summary/hospi[INVESTIGATOR_20112]  (if available  and  allowed  by [CONTACT_54443]/local  law)  
• Autopsy report (if available and allowed by [CONTACT_54443]/local  law)  
• Death certificate (if available and/or allowed by [CONTACT_54443]/local  law)  
 
Sufficient information will be required in order to properly classify the subject’s death. The  
Investigator shall classify each subject death per the following definitions:  
 
• Cardiac Death : A death directly related to the electrical or mechanical dysfunctio n of  the 
heart.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 64 of 111   
  
• Sudden Cardiac Death (SCD): Natural death due to cardiac causes, indicated by [CONTACT_169282]; preexisting heart 
disease may have been known to be present, but the time and mode of death are 
unexpected. If time of onset cann ot be determined, SCD will alternatively be defined as any 
unexpected cardiac death occurring out of the hospi[INVESTIGATOR_169242].  
• Non -sudden Cardiac Death : All cardiac deaths that are not classified as sudden deaths, 
including all cardiac deaths of hospi[INVESTIGATOR_169243].  
• Non -cardiac Death : A death not classified as a cardiac  death.  
• Unknown  Classification : Unknown  death  classification  is intended  for use  only  when  there  is 
insufficient or inadequate informati on to classify the  death.  
 
The CEC will review deaths and provide a final adjudication of the primary cause of death and 
cardiac classification. Regulatory reporting of Subject Deaths will be completed according to local 
regulatory requirements.  
 
Table 7: Adverse Event Reporting Requirements  
 
Serious Adverse Events (SAEs)  
Investigator submit to:  
Medtronic  All geographies: Report, without unjustified delay, all serious adverse events.  
IRB/REB/MEC  All geographies: Submit per local reporting requirement.  
Regulatory 
Authorities  All geographies: Submit per local reporting requirement.  
Sponsor submit to:  
IRB/REB/MEC  All geographies: Submit per local reporting requirement.  
Regulatory 
Authorities  All geographies: Submit per local reporting requirement.  
Serious Adverse Device Effects (SADEs)  
Investigator submit to:  
Medtronic  All geographies: Submit as soon as possible after the Investigator first learns of the 
event, and per local requirements  
Canada: SADEs on the patient, the user or any other person must be reported to the 
Regulator and to the Sponsor within 72 hours after it comes to the at tention of the 
qualified investigator.  
IRB/REB/MEC  All geographies:  Submit per local reporting requirement.  
Regulatory 
authorities  All geographies: Submit as soon as possible after the Investigator first learns of the 
event, and per local requirements  
Sponsor submit to:  
IRB/REB/MEC  All geographies:  Submit per local reporting requirement.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 65 of 111   
  
Regulatory 
authorities  Canada : All SADEs on the patient, the user or any other person: these must be 
reported  by [CONTACT_169283]  [ADDRESS_197656]  person  becomes  aware. 
Preliminary and final reporting to the Canadian Ministry of Health (Health Canada) of 
events occurrin g inside (always) or outside Canada (in case of corrective actions) 
that is related to a failure of the device or a deterioration in its effectiveness, or any 
inadequacy in its labeling or its directions for use and has led to the death or a 
serious  deteri oration  in the  state  of health  of a patient,  user  or other  person  or could 
do so were it to recur. Report a) within 10 days after awareness, if incident has led to 
death or a serious deterioration in the state of health of a patient, user or other 
person b ) within 30 days, if incident has not led to death or a serious deterioration in 
the  state  of health  of a patient,  user  or other  person,  but could  do so were  it to recur  
c) as soon as possible, if incident occurred outside of Canada and is related to a 
corrective action. (Medical Devices Regulation Mandatory Problem Reporting 59(1), 
59(2), 60 (1))  
All geographies: Submit per local reporting requirement.  
Unanticipated Adverse Device Effects (UADEs) and Unanticipated Serious Adverse Device Effects 
([LOCATION_003]DEs)  
Investigator submit to:  
Medtronic  US: Submit as soon as possible, but no later than within [ADDRESS_197657] learns of the event. (21 CFR 812.150(a)(1))  
Canada: [LOCATION_003]DEs on the patient, the user or any other person must be reported to 
the Regulator and to the Sponsor w ithin 72 hours after it comes to the attention of 
the qualified investigator.  
IRB/REB/MEC  US: Submit as soon as possible, but no later than within [ADDRESS_197658] learns of the event. (21 CFR 812.150(a)(1))  
All geographies: Submit per local reporting requirement.  
Sponsor submit to  
Investigator  All geographies: Notification as soon as possible and not later than [ADDRESS_197659]. (21 CFR 812.150(b)(1))  
IRB/REB/MEC  All geographies: Notification as soon as possible and not later than [ADDRESS_197660]. (21 CFR 812.150(b)(1))  
Regulatory 
authorities  US: Notification as soon as possible to FDA, but not later than [ADDRESS_197661]. (21 CFR 812.150(b)(1))  
Canada: All [LOCATION_003]DEs on the patient, the user or any other person; these must be 
reported by [CONTACT_169284] [ADDRESS_197662] person at Medtronic that 
becomes aware. Preliminary and final reporting to the Canadian Ministry of Health 
(Health Canada) of events occurring inside (always) or outside Canada (in case of 
corrective actions) that is related to a failure of the device or a deterioration in its 
effectiveness, or any inadequacy in its labeling or its directions for use and has led to 
the death or a seriou s deterioration in the state of health of a patient, user or other 
person or could do so were it to recur. Report a) within 10 days after awareness, if 
incident has led to death or a serious deterioration in the state of health of a patient, 
user or other person b) within 30 days, if incident has not led to death or a serious 
deterioration in the state of health of a patient, user or other person, but could do so 
were it to recur c) as soon as possible, if incident occurred outside of Canada and is 
related to a corrective action. (Canada Medical Devices Regulations, SOR/98 -282; 
Mandatory Problem Reporting 59(1), 59(2), 60 (1))  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 66 of 111   
  
Adverse Device Effects  
Investigator submit to:  
Medtronic  All geographies: Submit in a timely manner after the Investigator first learns of the 
effect.  
IRB/REB/MEC  All geographies: Submit per local reporting requirement.  
Regulatory 
authorities  All geographies: Submit per local reporting requirement.  
Sponsor submit to:  
IRB/REB/MEC  All geographies: Submit per local reporting requirement.  
Regulatory 
authorities  All geographies: Submit per local reporting requirement.  
All other reportable Adverse Events  
Investigator submit to:  
Medtronic  All geographies: Submit in a timely manner after the Investigator first learns of the 
event.  
Regulatory 
authorities  All geographies: Submit per local reporting requirement.  
IRB/REB/MEC  All geographies: Submit per local reporting requirement.  
Sponsor submit to:  
Regulatory 
authorities  All other geographies: Submit per local reporting requirement.  
 
 
Table 8:  Adverse Event Classification Responsibilities  
 
What is classified?  Who classifies?  Classification Parameters  
 
Relatedness  Investigator  Procedure related, System related, Cardiovascular 
related  
Sponsor  Procedure related, System related  
 
Seriousness  Investigator  SAE  
Sponsor  SAE, UADE/[LOCATION_003]DE, Device Deficiency with SADE 
potential  
 
Diagnosis  Investigator  Based on presenting signs and symptoms and other 
supporting data  
Sponsor  MedDRA term assigned based on the data provided 
by [CONTACT_169285], Non -Sudden Cardiac, Non -Cardiac, 
Unknown  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 67 of 111   
  
10.4.  Reporting of Device  Deficiencies  
Device deficiency (DD) information will be collected throughout the study and are to be reported to 
Medtronic, as per Table 9: Device Deficiency Reporting Requirements.  A Medtronic representative 
will review the device defici ency for completeness and accuracy and when necessary will request 
clarification and/or additional information from the Investigator. Note that device deficiencies that 
result in an adverse device effect (ADE) to the subject should be captured as an Advers e Event 
only.  
Device deficiencies that did not lead to an AE, but could have led to a Serious Adverse Device Effect 
(SADE) (i.e., if suitable action had not been taken, if intervention had not been made, or if the 
circumstances had been less fortunate) req uire immediate reporting. For device deficiencies that 
require immediate reporting, initial reporting may be done by [CONTACT_169286].  
 
Table 9: Device Deficiency Reporting Requirements  
 
Device Deficiencies and SADE Potential  
Investigator submit to:  
Medtronic  All geographies: Report, without unjustified delay, all device deficiencies that could 
have led to a serious adverse device effect  
Regulatory 
authorities  All geographies:  Submit per local reporting requirement.  
IRB/REB/MEC  All geographies:  Submit per local reporting requirement.  
Sponsor submit to:  
IRB/REB/MEC  All geographies: Submit per local reporting requirement.  
Regulatory 
authorities  Canada:  Any Device Deficiency that:  
 has resulted in any of the consequences characteristic of an SAE on 
the patient, the user or any other person; These must be reported  by 
[CONTACT_169284] [ADDRESS_197663]  be report ed by [CONTACT_169283] 
30 days from the date Medtronic becomes  aware.  
 
Preliminary and final reporting to the Canadian Ministry of Health (Health Canada) of 
events occurring inside (always) or outside Canada (in case of corrective actions) 
that is related to a failure of the device or a deterioration in its effectiveness, or any 
inadequacy in its labeling or its directions for use and has led to the death or a 
serious  deterioration  in the  state  of health  of a patient,  user  or other  person  or could 
do so were it to recur. Report a) within 10 days after awareness, if incident ha s led to 
death or a serious deterioration in the state of health of a patient, user or other 
person b) within 30 days, if incident has not led to death or a serious deterioration in 
the  state  of health  of a patient,  user or other person,  but could  do so were it to recur  
c) as soon as possible, if incident occurred outside of Canada and is related to a 
corrective action. (Canada Medical Devices Regulations, SOR/98 -282; Mandatory 
Problem Reporting 59(1), 59(2), 60 (1)).  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 68 of 111   
  
 All geographies: Submit per local reporting requirement.  
All Other Device Deficiencies  
Investigator submit to:  
Medtronic  All geographies: Submit in a timely manner after the Investigator first learns of the 
event.  
IRB/REB/MEC  All geographies: Submit per local reporting requirement.  
Regulatory 
authorities  All geographies: Submit per local reporting requirement.  
 
 
10.5.  Reporting of Product  Complaints  
In geographies where devices are market -released, product complaint reporting is applicable. This 
includes when an AE is related to a market -released device during the study. The reporting of 
product complaints is not part of the Study and should be done i n addition to the Adverse Event 
reporting requirements. Refer to local regulations for reporting requirements.  
Product Complaint: Any written, electronic or oral communication that alleges deficiencies related 
to the identity, quality, durability, reliabil ity, safety, effectiveness or performance of a medical 
device that has been placed on the market.  
It is the responsibility of the Investigator to report all product complaint(s) associated with a 
market -released medical device distributed by [CONTACT_13735], reg ardless whether they are related to 
intended use, misuse or abuse of the product. Reporting must be performed immediately and via 
the regular channels for market -released products.  
Medtronic will notify the regulatory authorities (e.g. FDA, Health Canada) as applicable for the 
following incidents immediately upon learning of them:  
• Any malfunction or deterioration in the characteristics and/or performance of a device, as 
well as any inadequacy in the labeling or instructions for use which led or might have l ed to 
the  death  or serious  deterioration  in the  state  of health  of a patient,  user,  or other  person.  
• Any technical or medical reason resulting in withdrawal of a device from the market by [CONTACT_13989].  
• A serious deterioration in the state of heath  includes:  
o Life -threatening illness or  injury  
o Permanent impairment of a body function or permanent damage to a body 
structure  
o A condition  necessitating  medical  or surgical  intervention  to prevent  permanent 
impairment of a body function or permanent damage to a body  structure  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 69 of 111   
  
 
 
An independent Clinical Events Committee (CEC) will review and adjudicate all adverse events as 
well as all deaths for subjects participating in the study.  
The CEC wil l consist of a minimum of three (3) non -Medtronic employed physicians that are not 
participating Investigators for the study, including a CEC chairperson. Medtronic personnel may 
facilitate and participate in a CEC meeting but will be non -voting members.  
For adverse events and deaths reviewed by [CONTACT_15741], Medtronic will provide the CEC with the 
Investigator’s description and classification. The CEC is responsible for reviewing the 
Investigator’s assessment and supportive documentation (when available), revie wing applicable 
definitions, and determining final classifications for all adjudication parameters. Additionally, the 
CEC will provide an adjudication of the death classification for all reported deaths including primary 
cause of death and cardiac classifi cation.  
If the CEC disagrees with the Investigator’s classification of the event, the rationale will be 
provided to the Investigator. If the Investigator agrees with the CEC’s adjudication, the eCRF 
documenting the event will be updated accordingly.  
If the Investi gator does not agree with the CEC’s adjudication classification, both determinations 
will be provided within the final report; however, the CEC’s adjudication will be used for data 
analysis. The disagreement will also be included in reporting to IRB/REB/ME Cs and regulatory 
authorities, if required.  11.  Clinical Events Committee  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 70 of 111   
  
 
 
A separate Statistical Analysis Plan (SAP) will be developed to further describe statistical methods, 
pre -specified data handling rules, and pre -specified analyses that will be included in study reports. 
Any deviation f rom the pre -specified statistical analyses will be noted in the study report.  
Additional exploratory analyses of the data may be conducted as deemed appropriate.  
 
As this is a feasibility study, analysis of accruing data will be allowed. Analyses are plann ed at the 
following time points (though only select objectives may be analyzed at the first 2 analyses):  
• After  completion  of the  first  [ADDRESS_197664]  index  procedures  and  1 week  follow -up visit  
• After completion of all [ADDRESS_197665] index procedures and 1 week follow -up visit  
• After  completion  of all subject  follow -up visits  through  12 month  follow -up visit  12.  Statistical Design and  Methods  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version  1.0,  14JUN2017  Page 71 of 111   
  
12.1.  Primary  Objective  
Estimate the incidence of ArcticLine Catheter -related and ArcticLine cryoablation procedure - 
related serious adverse eve nts (SAEs) with an onset date within [ADDRESS_197666] -procedure, as adjudicated by [CONTACT_34164] (CEC), described as 
follows:  
• Atrioesophageal  fistula  
• Cardiac  perforation/tampona de 
• Cerebrovascular  accident  
• Death  
• Esophageal  injury  
• Major  bleeding  
• Myocardial  infarction  
• Pericarditis  
• Phrenic nerve injury (ongoing at hospi[INVESTIGATOR_47850])  
• Transient ischemic  attack  
• Vagal nerve injury resulting in esophageal dysmotility or  gastroparesis  
• Vascular access  complications  
 
Sample Size  
 
The sample size of [ADDRESS_197667] 
preliminary safety and effectiveness data on the ArcticLine Catheter’s use in both the left and right 
atrium. Assuming there are 30 ArcticLine cryoablation procedures  in the study and the SAE rate is 
3.3% (1/30 subjects: the rate of cryoablation procedure events in the STOP AF pi[INVESTIGATOR_16076] [PMA  
#P100010] was 3.1%), the exact 95% confidence interval will have a width of 17%.  
 
Analysis Methods  
 
The percentage of cathete r related and cryoablation procedure related SAEs will be calculated as 
the number of procedures with at least one SAE meeting the endpoint definition divided by [CONTACT_169287]. Each procedure will count, so subjects with repeat 
cryo ablations will contribute more than once to the denominator. Exact methods will be used to 
construct a 95% confidence interval for the percentage of procedures with an SAE.  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197668] occurred once the ArcticLine Catheter is introduced into the vasculature.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version  1.0,  14JUN2017  Page 73 of 111   
  
12.2.  Ancillary Objective  #[ADDRESS_197669] confirmed block at the roof line and posterior wall line (“roof/wall”) via 
periprocedural assessment of posterior wall isolation at the completion of the cryoablation 
procedure to be considered an acut e treatment success.  
Analysis Methods  
 
The percentage of acute roof/wall treatment successes will be calculated as the number of 
roof/wall procedures achieving success divided by [CONTACT_169288]/wall wa s attempted. Exact methods will be used to construct a 95% 
confidence interval for the percentage.  
Determination of Patients for Analysis  
 
All subjects undergoing an ArcticLine cryoablation procedure of the roof/wall will be included. An 
ArcticLine cryoabl ation procedure of the roof/wall is considered to have occurred once an 
ArcticLine cryoapplication at the roof and/or wall begins. Only the first ArcticLine cryoablation 
procedure of the roof/wall per subject will be included.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version  1.0,  14JUN2017  Page 74 of 111   
  
12.3.  Ancil lary Objective  #[ADDRESS_197670] a 95% confidence in terval for the percentage.  
Determination of Patients for Analysis  
 
All subjects undergoing an ArcticLine cryoablation procedure of the mitral isthmus will be included. 
An ArcticLine cryoablation procedure of the mitral isthmus is considered to have occurre d once an 
ArcticLine cryoapplication at the mitral isthmus begins. Only the first ArcticLine cryoablation 
procedure of the mitral isthmus per subject will be included.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version  1.0,  14JUN2017  Page 75 of 111   
  
12.4.  Ancillary Objective  #[ADDRESS_197671] a 95% confidence 
interval for the percentage.  
Determination of Patients for Analysis  
 
All subjects undergoing an ArcticLine cryoablation procedure of the CTI will be included. An 
ArcticLine cryoablation procedure of the CTI is considered to have  occurred once an ArcticLine 
cryoapplication at the CTI begins. Only the first ArcticLine cryoablation procedure of the CTI per 
subject will be included.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version  1.0,  14JUN2017  Page 76 of 111   
  
12.5.  Ancillary Objective  #4 
Characterize chronic treatment success of the ArcticLine Cathete r in patients with demonstrated 
entrance block of all pulmonary veins.  
Endpoint Definition  
 
AF/AFL/AT epi[INVESTIGATOR_169212] [ADDRESS_197672] statistics will  be used to summarize the percentage of patients without AF/AFL/AT and 
cumulative time spent in AF/AFL/AT as collected from the 12 month Holter data.  
Determination of Patients for Analysis  
 
• All subjects undergoing an ArcticLine cryoablation procedure and who meet the following 
criteria will be included in the  analysis:  
o Confirmed acute entrance block of all pulmonary  veins  
o Confirmed  acute  posterior  wall  isolation  (i.e.  roof  line  and  posterior  wall  line 
conduction  block)  
o Confirmed acute bi -directional conduction block at the mitral isthmus,  if 
applicable  
o Available 12 month Holter  data  
• Note: An ArcticLine cryoablation procedure is considered to have occurred once  the 
ArcticLine Catheter  is introduced into the  vasculature.  
• Note:  For  subjects  who  did not  receive  CTI  ablation  with  ArcticLine  Catheter,  documented 
occurrence and treatment of typi[INVESTIGATOR_169244] -sided cavotricuspid isthmus dependent atrial 
flutter during follow -up will not contribut e to this endpoint if confirmed by [CONTACT_169289].  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version  1.0,  14JUN2017  Page 77 of 111   
  
12.6.  Ancillary Objective  #5 
Estimate the incidence of ArcticLine Catheter -related and ArcticLine cryoablation procedure - 
related serious adverse events (SAE) through the 12 month visit.  
Endpoint Definition  
 
ArcticLine Catheter -related or ArcticLine cryoablation procedure -related SAEs , as adjudicated by 
[CONTACT_34164] (CEC).  
Analysis Methods  
 
Kaplan -Meier methods will be used to estimate event percentages separately for each of the 
events listed above. Time [ADDRESS_197673] documented time in the study (e.g., follow -up, exit, death). Though 
Kaplan -Meier methods will be used, only point estimates for the rates at 12 months (not graphs) 
will be reported.  
Determination of Patients for Analys is 
 
All subjects undergoing an ArcticLine cryoablation procedure will be included. An ArcticLine 
cryoablation procedure is considered to have occurred once the ArcticLine Catheter is introduced 
into the vasculature.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version  1.0,  14JUN2017  Page 78 of 111   
  
12.7.  Ancillary Objective  #6 
Characterize procedural data:  
• Total procedure  time  
• Total ArcticLine Catheter use  time  
• Left atrial dwell  time  
• Total fluoroscopy  time  
• Total fluoroscopy time during ArcticLine Catheter  use  
• Application  duration  
• Number of  applications  
• Fluoroscopy  dose  
 
Endpoint Definition  
 
• Total procedure time is defined as time from first venous access to time of last catheter 
removal.  
• Total ArcticLine Catheter use time is defined as cumulative time from each introduction of 
ArcticLine Catheter into the body to its  remo val.  
• Left  atrial  dwell  time  is defined  as time  from  transseptal  puncture  to time  of removal  of last 
sheath/catheter from the left  atrium.  
• Total fluoroscopy time is defined as total fluoroscopy time used during  the procedure.  
• Total fluoroscopy time during ArcticLine Catheter use is defined as the cumulative 
fluoroscopy  time  from each  introduction  of ArcticLine  Catheter  into  the  body  to its 
removal.  
• Application duration is defined as total duration in which cryoablation from the ArcticLine 
Catheter  is applied  to cardiac  tissue  overall  and  individually  to each  target  area.  
• Number of applications is defined as the total number of times in which the ArcticLine 
Catheter was used to ablate cardiac tissue overall and individually to each target  area.  
• Total  fluoroscopy  dose  is defined  as the  amount  of radiation  deposited  into  the  tissue, 
measured in Gy or mGy  units.  
Analysis Methods  
 
Standard statistics (e.g., mean, standard deviation) will be used to summarize each variable. Data 
from index cryoablations and repeat cryoablations will be reported separately.  
Determination of Patien ts for Analysis  
 
All subjects undergoing a cryoablation procedure will be included. A cryoablation procedure is 
considered to have occurred once the skin is punctured.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version  1.0,  14JUN2017  Page 79 of 111   
  
12.8.  Ancillary Objective  #7 
Estimate the incidence of adverse events (AEs) through the 12 month visit.  
 
Endpoint Definition  
 
Characterize adverse events through the 12 month visit, described as follows:  
 
• Atrioesophageal  fistula  
• Cardiac  perforation/tamponade  
• Cerebrovascular  accident  
• Coronary artery  spasm  
• Death  
• Esophageal  injury  
• Lung injury (including  hemoptysis)  
• Major  bleeding  
• Myocardial  infarction  
• Pericarditis  
• Phrenic nerve injury (ongoing from hospi[INVESTIGATOR_47850])  
• Pulmonary vein  stenosis  
• Symptomatic persistent iatrogenic atrial septal  defect  
• Transient ischemic  attack  
• Vagal nerve  injury  
• Vascular access  complications  
 
Analysis Methods  
 
Kaplan -Meier methods will be used to estimate event percentages. Time [ADDRESS_197674] documented time in the 
study (e.g., follow -up, exit, death). Though Kaplan -Meier methods will be used, only point 
estimates for the percentages at 12 months (not graphs) will be reported.  
Det ermination of Patients for Analysis  
 
All subjects undergoing an ArcticLine cryoablation procedure will be included. A cryoablation 
procedure is considered to have occurred once the skin is punctured.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 80 of 111   
  
 
 
13.1.    Statement(s) of Compliance  
The study will be conducted in compliance with international ethical and scientific quality 
standards, known as good clinical practice (GCP). GCP includes review and approval by [CONTACT_169290]/REB/MEC before initiating a study, continuing review of an ongoing study by [CONTACT_113834]/REB/MEC, and obtaining and documenting the freely given informed consent of a subject 
before initiating the study.  
The study will b e conducted according to federal, national and local laws, regulations, standards, 
and requirements of the countries/geographies where the study is being conducted. For all 
geographies, the principles of the Declaration of Helsinki have been implemented th rough the 
patient informed consent (IC) process, IRB/REB/MEC approval, study training, clinical trial 
registration, preclinical testing, risk -benefit assessment and publication policy.  
All geographies will follow and comply with:  
 
• Principles  of Declaration  of Helsinki  (including  privacy  and  data  protection  laws),  or the  laws 
and regulations of each participating country, whichever affords greater protection for the 
study  subjects  
• 21 CFR Part 11 (Electronic Records, Electronic  Signatures)  
• The procedures desc ribed within this  CIP  
• Local IRB/REB/MEC  requirements  
 
All participating geographies will make study data available to the regulatory body such as FDA or 
Health Canada if the regulatory body deems an onsite inspection necessary. The regulatory body 
will be able to inspect records at clinical centers around the  world to resolve any uncertainties 
about whether the study was conducted in accordance with good clinical practice.  
In addition to the regulatory requirements outlined above, the study will be conducted in 
compliance with relevant local laws.  These inclu de but are not limited to:  
• In Canada, the Medical Devices Regulations, 1998 (SOR/98 -282), 59(1), 59(2), 60(1), and the 
Canadian Regulatory Guidelines for Mandatory Medical Device Problem Reporting for 
Medical Devices,  2011.  
• Declaration of Helsinki  2013  
• In the [LOCATION_002] and Canada, US FDA 21 CFR  Parts  
o 50: Protection of Human  Subjects  
o 56: Institutional Review  Boards  
o 812: Investigational Device  Exemptions  13.  Ethics  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197675] (FDAAA) and Declaration of Helsinki on 
http://clinicaltrials.gov  (PL 110 -85, Section 810(a)).  
Approval of the Clinical Investigation Plan (CIP) is required from the following groups prior to any 
study procedures at a study center:  
• Health Canada or  FDA  
• Medtronic  
• Principal Investigators (where required by [CONTACT_169291])  
• An independent  IRB/REB/MEC  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197676] 
therefore be allowed access to the subjec ts’ case histories (clinic and hospi[INVESTIGATOR_1097], and other 
source data/documentation) upon request as per the IC Form, Research Authorization (where 
applicable) and Clinical Trial Agreement. The Principal Investigator [INVESTIGATOR_169245].  
Frequency of monitoring visits may be based upon subject enrollment, duration of the study, study 
compliance, number of adverse events, number of deviations, findings from previous monitoring 
visits and any suspected inconsistency in data that  requires investigation. Regulatory documents 
may be reviewed at each study center. Monitoring for the study may include, but not limited to, site 
qualification visits, site initiation visits, interim monitoring visits, and closeout visits, will be done in  
accordance to the study -specific monitoring plan.  
Monitoring visits may be conducted periodically to assess center study progress, the Investigator’s 
adherence to the CIP, regulatory compliance including but not limited to IRB/REB/MEC approval 
and review of the study, maintenance of records and reports, and review of source documents 
against subject eCRFs. Monitors review center regulatory and study compliance by [CONTACT_131495] -compliance and communicating those findings along with recommendat ions for 
preventative/corrective actions to center personnel. Monitors may work with study personnel to 
determine appropriate corrective action recommendations and to identify trends within the study 
or at a center.  
 
14.2.  Data  Management  
Data will be collected using an electronic data management system for clinical studies. eCRF data 
will be stored in a secure, password -protected database which will be backed up nightly. Data will 
be reviewed using programmed and manual data checks. Data q ueries will be made available to 
centers for resolution.  
Data collected by [CONTACT_54451], Patient Activated Ambulatory Monitors and ECGs will be managed and 
over -read by a core lab. Final classification of recurrent AF/AT/AFL will be stored in the study 
database . 14.  Study  Administration  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197677] party designated by 
[CONTACT_54452] a key coded form, unless it’s impossible to make it anonymous, for instance, where 
the subject’s name [CONTACT_169309], such as fluoroscopy images. In the 
case that de -identifying is impossible or involves a disproportionate effort, files containing 
personal data of subjects shall only be made accessible to authorized persons (secured role -based 
access).  
Procedures in the CIP require source documentation. Source documentation will be maintained at 
the center. Source documents, which may include worksheets, subject medical records, console 
files, must be created and maintained by [CONTACT_169292].  
The data reported on the eCRFs shall be derived from source documents and be consistent with 
these source documents, and any discrepancies shall be explained in writing. The eCRF may be 
considered source for the following data collect ion elements:  
• Database generated subject reference  ID 
• Esophageal  temperature  
• Investigator  assessment  of adverse  event  or death  relatedness  and  severity  
• Date center became aware of the adverse event, device deficiency or  death  
• Reason for study  deviation  
• If Arctic Front Advance and Achieve/Achieve Advance is used, time of isolation of the 
cryoablation  catheter  
• Investigator’s assessment of conduction  block  
 
When copi[INVESTIGATOR_41090] -outs of the source documents are made, center personnel must ensure that 
all copi[INVESTIGATOR_169246].  
The sponsor or a regulatory authority may audit or inspect the study center to eval uate the 
conduct of the study. The clinical Investigator(s)/institution(s) shall allow study related monitoring, 
audits, IRB/REB/MEC review and regulatory inspection by [CONTACT_169293]/documents.  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197678] packaging for the AFA, Freezor MAX and 
sheath devices.  
Canada: Medtronic of Canada is a wholly owned subsidiary of Medtronic, Inc., which as the parent 
company of such entity maintains appropriate ge neral liability insurance coverage as required 
under applicable laws and regulations and will comply with applicable local law and custom 
concerning specific insurance coverage. If required, a General Liability insurance 
statement/certificate will be provi ded to the REB/MEC.  
US: Medtronic Inc. maintains appropriate clinical study liability insurance coverage as required 
under applicable laws and regulations and will comply with applicable law and custom concerning 
specific insurance coverage. If required, a  Clinical Trial Insurance statement/certificate will be 
provided to the IRB.  
The study is conducted in multiple countries; therefore, reimbursement and indemnification will be 
addressed on a country specific basis in the study documents and center Clinical  Trial Agreements.  
 
14.5.  CIP  Amendments  
Approval of subsequent revisions to the CIP is required at each study center from the following 
groups prior to implementation of the revised CIP at the center:  
• Medtronic  
• Principal Investigators (where required by [CONTACT_169291])  
• Geography -specific  regulatory  authorities  (if regulatory  approval  is required)  
• An independent  IRB/REB/MEC  
 
If a CIP amendment occurs, center personnel will need to be re -trained as necessary, and will need 
to submit any changes to their IRB/REB/MEC as required by [CONTACT_942].  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197679] -protected document management 
system, and paper documents (where applicable) will be stored in stored in secured file cabinets at 
Medtronic during the course of this study. After closure of the study Medtronic will archive records 
and reports indefinitely.  
Investigator Records  
The Investigator is responsible for the preparation and retention of the records cited below. All the 
below records, except for case history records and eCRFs, should be kept in the Investigator Site 
File (i.e.,  the study binder provided to the Investigator) or Subject Study Binder. CRFs must be 
maintained and signed electronically within the electronic data capture system during the study.  
The following records are subject to inspection and must be retained for a period of two years (or 
longer as local law or hospi[INVESTIGATOR_54387]) after the date on which the investigation is 
terminated or the date that the records are no longer required for purposes of supporting a pre - 
market approval application:  
• All correspondence between the IRB/REB/MEC, sponsor, monitor, local regulatory 
agencies  and  the  Investigator  that  pertains  to the  investigation,  including  required  reports  
• Subject’s case history records,  including:  
• IC Form signed and dated by  [CONTACT_1130]  
• Observations of adverse events and device  deficiencies  
• Medical  history  
• Procedure and follow -up data  
• Documentation of the dates and rationale for any deviation from the  CIP  
• Reports of adverse  events  
• Subject screening logs (if  used)  
• List of investigation  centers  
• Financial disclosure of  Investigators  
• Device Disposition  Logs  
• All approved  versions  of the  CIP,  IC, and  Investigator’s  Brochure/Report  of Prior  
Investigations  
• Signed and dated Clinical Trial Agreement and Investigator  Statement  
• Current curriculum vitae of  Investigators  
• Documentation of delegated  tasks  
• IRB/REB/MEC approval documentation. Written information that the Investigator or other 
study  staff,  when  member  of the  IRB/REB/MEC,  did not  participate  in the  approval  process.  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197680] include the IRB/REB/MEC composition,  where required per 
local law.  
• Regulatory authority notification, correspondence and approval, where required per  local 
law  
• Study training records for center  staff  
• Insurance certificates (where requested by [CONTACT_36985]/REB/MEC)  
• Any other records that FDA and local regulatory agencies require to be  maintained  
• Final Study Report including the statistical  analysis  
 
Investigator Reports  
The Investigator is responsible for the preparation (review and signature) and submission to the 
sponsor of all case report forms, adverse events, device deficiencies, deaths, and any deviations 
from the clinical investigation plan. If any action is taken by [CONTACT_2717]/EC with respect to this clinical 
study, copi[INVESTIGATOR_169247] a timely manner. 
Reports are subject to inspection and to the retention requirements as described above for 
investigator records.  
The investigator shall prepare and submit in a complete, accurate and timely manner the reports 
listed in this section.  
 
Table 10: Investigator reports applicable for all geographies per Medtronic requirements  
 
Report  Submit to  Description/Constraints  
 
Withdrawal of 
IRB/EC approval   
Sponsor and 
Relevant 
authorities  The Investigator must report a withdrawal of 
approval by [CONTACT_3488]/EC of the 
Investigator’s part of the investigation within 5 
working days.  
 
 
 
 
Study deviations   
 
 
 
Sponsor and 
IRB/EC  Any deviation from the clinical investigation plan 
shall be recorded together with the explanation of 
the deviation.  Notice of deviations from the CIP 
to protect the life or physical wellbeing of a 
subject in an emergency shall be given as soon as 
possibl e, but no later than 5 working days after 
the emergency occurred. Except in such 
emergency, prior approval is required for changes 
in the plan or deviations.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 87 of 111   
  
Report  Submit to  Description/Constraints  
 
Final report  Sponsor, 
IRBs/ECs, and 
Relevant 
Authorities   
This report must be submitted within 3 months of 
study completion or termination.  
Refer to Section 10 for adverse event, complaint, and device deficiency reporting.  
 
 
Table 11: Additional Investigator reports applicable to the [LOCATION_002]  
 
Report  Submit to  Description/Constraints  
 
Withdrawal of 
IRB/EC approval   
Sponsor  The Investigator must report a withdrawal of 
approval by [CONTACT_3488]/EC of the 
Investigator’s part of the investigation within 5 
working days.  (21 CRF 812.150 (a)(2)).  
 
Progress report   
Sponsor and 
IRB/EC  The Investigator must submit this report to the 
sponsor and IRB at regular intervals, but in no 
event less than yearly. (21 CFR 812.150 (a)(3)).  
 
 
 
 
 
 
Study deviations   
 
 
 
 
 
Sponsor and 
IRB/EC  Notice of deviations from the clinical  investigation 
plan to protect the life or physical wellbeing of a 
subject in an emergency shall be given as soon as 
possible, but no later than [ADDRESS_197681] be approved by [CONTACT_13735], the 
IRB/EC, and the FDA/applica ble regulatory 
authorities. If the deviation does not affect these 
issues then only Medtronic must approve it. (21 
CFR  812.150(a)(4))  
Failure to obtain 
Informed  Sponsor and 
IRBs/ECs  If an Investigator uses a device without obtaining 
a signed Informed Consent Form, the  Investigator  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 88 of 111   
  
Report  Submit to  Description/Constraints  
Consent Form 
prior to 
investigational 
device use   shall report such use within 5 working days after 
device use.  (21 CFR 812.150(a)(5))  
 
Final report  Sponsor, 
IRBs/ECs, and 
Relevant 
Authorities  This report must be submitted within 3 months of 
study completion or termination of the 
investigation or the Investigator’s part of the 
investigation.  (21 CFR 812.150(a)(6))  
 
Sponsor Records  
Medtronic shall maintain the following accurate, complete, and current records:  
• All correspondence  which  pertains  to the  investigation  
• Signed Investigator Trial Agreements, financialdisclosureofInvestigators,andcurrent 
signedanddated(Europeonly)curriculum vitae of Principal Investigator [INVESTIGATOR_169248]  (as required  by [CONTACT_169291]),  and  Delegated 
Tasks  List  
• All approved  versions  of the  ICF,  and  other  information  provided  to the  subjects 
and advertisements, including  translations.  
• All approved  versions  of the  Clinical  Investigation  Plan  and  study  related  reports,  
Investigator’s Brochure/Report of Prior Investigation Summary  
• All case report forms and supporting documentation submitted by [CONTACT_1697], 
samples  of Informed  Consent  Forms,  and  other  information  provided  to the  subjects  
• Copi[INVESTIGATOR_169249]/EC  approval  letters  and  relevant  IRB/EC  correspondence  and 
IRB/EC voting list/roster/letter of  assurance  
• Names  of the  institutions  in which  the  clinical  investigation  will  be conducted  
• Regulatory  authorities  correspondence,  notification  and  approval,  as required  by [CONTACT_169294]  
• Insurance  certificates  
• Names/contact [CONTACT_169295]  
• Monitoring visit reports and follow -up letters  
• Forms  for reporting  any  adverse  events  and  adverse  device  effects  
• Statistical  analyses  and  underlying  supporting  data.  
• Final  report  of the  clinical  investigation  
• Study  training  records  for center  personnel  and  Medtronic  personnel  involved  in the 
study  
• Any  other  records  that  local  regulatory  agencies  require  to be maintained  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197682] of reviewing 
IRB/EC, regulatory agency or FDA, provide accurate, compl ete and current information about any 
aspect of the investigation. Safety data reporting requirements are listed in the adverse event 
section.  
 
Table 12: Sponsor reports for the [LOCATION_002]  
 
Report  Submit to  Description/Constraints  
 
Withdrawal of 
IRB/EC approval  Investigators, 
IRB/EC,  
FDA, and 
relevant 
authorities   
Notification within five working days. (21 CFR 
812.150(b)(2))  
 
Withdrawal of 
FDA approval  Investigators, 
IRB/EC, and 
relevant 
authorities   
Notification within 5 working days. (21 CFR 
812.150(b)(3))  
 
Investigator List   
FDA  Submit at [ADDRESS_197683] of the 
names and addresses of all Investigators 
participating in the investigation. (21 CFR 
812.150(b)(4))  
Progress Reports  IRB/EC and 
FDA  Progress reports will be submitted at least 
annually.  (21 CFR 812.150(b)(5), 812.36(f)  
 
 
 
Recall and device 
disposition  Investigators, 
Head of 
Institution, 
IRB/EC,  
relevant 
authorities, 
and  
FDA   
 
Notification within [ADDRESS_197684] that an 
Investigator return, repair, or otherwise dispose 
of any devices.  (21 CFR 812.150(b)(6))  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 90 of 111   
  
Report  Submit to  Description/Constraints  
Failure to obtain 
Informed 
Consent Form   
FDA  Investigator’s report will be submitted to FDA 
within five working days of notification. (21 CFR 
812.150(b)(8))  
 
 
Final report  Investigators, 
IRB/EC,  
Regulatory 
authorities 
upon request, 
and FDA  Medtronic will notify FDA within 30 working days 
of the completion or termination of the 
investigation. A final report will be submitted to 
the FDA, investigators, and IRBs within 6 months 
after completion or termination of this study. (21 
CFR 812.150(b)(7 )) 
 
 
 
Study deviation   
 
 
Investigators  Ensure that all deviations from the clinical 
investigation plan are reviewed with the 
appropriate clinical investigator(s), are reported 
on the case report forms and the final report of 
the clinical investigation.  
Site specific study deviations will be sub mitted to 
investigators periodically.  
 
Other   
IRB/EC, and 
FDA  Accurate, complete, and current information 
about any aspect of the investigation. (21 CFR 
812.150(b)(10))  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 91 of 111   
  
Table 13: Sponsor reports for Canada  
 
Report  Submit to  Description/Constraints  
 
Premature 
termination or 
suspension of the 
clinical 
investigation  Investigators, 
Ethics 
Committee, 
Relevant 
authorities, 
and  
Head of the 
Institution  Provide prompt notification of termination or 
suspension and reason(s).  
 
Recall and device 
disposition  Investigators, 
Ethics 
Committee  Notification within [ADDRESS_197685] that an 
investigator return, repair, or otherwise dispose 
of any devices.  
 
 
Study deviation   
 
Investigators  Ensure that all deviations from the Clinical 
Investigation Plan are reviewed with the 
appropriate clinical investigator(s), are reported 
on the case report forms and the final report of 
the clinical investigation . 
Site specific study deviations will be sub mitted to 
investigators periodically.  
Medtronic Confidential  
056-F275, v3.[ADDRESS_197686] Operating 
Procedures and as indicated in the Clinical Trial Agreement.  
Publication Committee  
 
Medtronic may form the ArcticLine Feasibility Study Publication Committee from the study 
Investigators. Medtronic personnel may serve as members of the committee. This committee will 
manage study publications with the goal of publishing findings from the data. The Publication 
Committee will develop the final Publication Plan as a sep arate document.  
The Publication Committee’s role is to: 1) manage elements addressed in the publication plan as 
outlined in this section, 2) develop the final Publication Plan under separate cover, 3) execute the 
Publication Plan, 4) oversee the publicatio n of primary and ancillary study results, 5) review and 
prioritize publication proposals, 6) provide input on publication content, and 7) determine 
authorship. In addition, the committee will apply and reinforce the authorship guidelines set forth 
in the P ublication Plan.  
Membership in the Publication Committee does not guarantee authorship. The committee will 
meet as needed.  
Management of Primary and Ancillary Publications  
 
The Publication Committee reviews, prioritizes, and manages all publications includ ing primary and 
ancillary publications.  Primary publications are those that address analyses of the primary 
objective and ancillary objectives as specified in the CIP. An ancillary publication is any publication 
that does not address the study objectives identified in the CIP. They include publications 
proposed and developed by [CONTACT_169296], clinicians participating in this 
clinical study, and clinicians not participating in this clinical study. The committee will work with 
Medtr onic to ensure that requests do not present conflicts with other proposals, are not 
duplicative, and to determine which ancillary publication proposals, if any, will be supported.  
The committee may decide that no publications, including abstracts, will be published prior to the 
end of the study or with individual center data. Requests for publications on study objectives 
utilizing subset data (e.g., regional) will be evaluated for s cientific validity and the ability of 
Medtronic to provide resources.  
Criteria for Determining Authorship  
 
Publications will adhere to authorship criteria defined by [CONTACT_65646] (ICMJE, Uniform requirements for ma nuscripts submitted to biomedical journals,  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 93 of 111   
  
www.icmje.org). Individual authorship criteria defined by [CONTACT_131503].  
Authors, including Medtronic personnel, must at a mi nimum meet all the conditions below:  
 
• Substantial  contribution  to conception  and  design,  or acquisition  of data,  or analysis  and 
interpretation of  data  
• Drafting the article or revising it critically for important intellectual  content  
• Final approval of the version to be  published  
• Agreement to be accountable for all aspects of the work in ensuring that questions related 
to the accuracy or integrity of any p art of the work are appropriately investigated and 
resolved  
 
Decisions regarding authorship and contributorship will be made by [CONTACT_942]. The selected 
authors will be responsible for drafting the publication. All selected authors must fulfill the 
authorship conditions stated above to be listed as authors, and a ll contributors who fulfill the 
conditions must be listed as authors.  
All Investigators not listed as co -authors will be acknowledged as the “Medtronic ArcticLine 
Feasibility Study Investigators” and will be individually listed according to the guidelines of the 
applicable scientific journal when possible and affiliation. Any other contributors will be 
acknowledged by [CONTACT_169297].  
Transparency  
 
Transparency of study results will be maintained by [CONTACT_54465]:  
 
• a final report,  describing  the  results  of all objectives  and  analysis,  will  be distributed  to all 
Investigators and IRB/REB/MECs of participating countries when required by [CONTACT_169291]  
• registering  and  posting  the  study  results  on ClinicalTrials.gov  based  on the  posting  rules 
stipulated  
• submitting for publication the primary study results after the study  ends  
• disclosing conflicts of interest (e.g., financial) of the co -authors of publications according to 
the policies set forth by [CONTACT_169298] d conferences  
• making  an individual  center’s  study  data  accessible  to the  corresponding  Investigator  after  
the completion of the study, if requested.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 94 of 111   
  
14.8.  Suspension or Early  Termination  
 
14.8.1.  Early Termination or  Suspension  
Early termination is the closure of a clinical study that occurs prior to meeting defined endpoints. 
This is possible for the whole study or a single center. Suspension is a temporary postponement of 
study activities related to enrollment. This is possible  for the whole study or a single center. If 
suspension is lifted, the Investigator shall assess whether to continue the clinical study at their 
center.  
 
14.8.2.  Study -Wide Termination or  Suspension  
Possible reasons for considering study suspension or termination o f the study include but are not 
limited to:  
• Adverse  events  associated  with  the  system  or product  under  investigation  which  might 
endanger the safety or welfare of the  subject  
• Observed/suspected performance different from the product’s  design intent  
• Decision by [CONTACT_54467] (where the study is operating under regulatory 
body  authority)  
• Technical issues during the manufacturing  process  
 
14.8.3.  Investigator/Center Termina tion or  Suspension  
Possible reasons for clinical Investigator or center termination or suspension include but are not 
limited to:  
• Failure to obtain IRB/REB/MEC annual renewal of the  study  
• Persistent  non -compliance  to the  CIP  (e.g.  failure  to adhere  to inclusion/exclusion  criteria, 
failure to follow subjects per visit  schedule)  
• Lack of  enrollment  
• Noncompliance  to regulations  and  the  terms  of the  Clinical  Trial  Agreement  (e.g.  failure  to 
submit data in a timely manner, failure to resolve data queries and monitoring findings in a 
timely  manner)  
• IRB/REB/MEC suspension of the  center  
• Fraud  or fraudulent  misconduct  is discovered  (as defined  by [CONTACT_169299])  
• Investigator request (e.g. no longer able to support the  study)  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 95 of 111   
  
14.8.4.  Procedures for Termination or  Suspension  
 
[IP_ADDRESS].  Medtronic -Initiated and Regulatory  Authority -Initiated  
• Medtronic  will  promptly  inform  the  clinical  Investigators  of the  termination  or suspension 
and the reasons and inform the regulatory authority(ies) where  required.  
• In the case of study termination or suspension for reasons other than a temporary 
IRB/REB/MEC approval lapse, the Investigator will promptly inform the  IRB/REB/MEC.  
• In the case of study termination, the Investigator must inform the subjects and may inform 
the personal physician of the subjects to ensure appropriate care and follow -up is  provided.  
• In the  case  of a study  suspension,  subject  enrollment  must  stop  until  the  suspe nsion  is 
lifted by  [CONTACT_13735].  
• In the case of a study suspension, enrolled subjects should continue to be followed out of 
consideration of their safety, rights and  welfare.  
 
[IP_ADDRESS].  Investigator -Initiated  
• The  Investigator  will  inform  Medtronic  and  provide  a detailed  written  explanation  of the 
termination or  suspension.  
• The Investigator will promptly inform the institution (where required per regulatory 
requirements).  
• The Investigator will promptly inform the  IRB/REB/MEC.  
• The  Investigator  will  promptly  inform  the  regulatory  authorities  (where  required  per 
regulatory  requi rements).  
• The Investigator will promptly inform the subjects and/or the personal physician of the 
subjects to ensure appropriate care and follow -up is  provided.  
• In the  case  of a study  suspension,  subjects  enrolled  should  continue  to be followed  out  of 
consideration of their safety, rights and  welfare.  
 
[IP_ADDRESS].  IRB/REB/MEC -Initiated  
• The  Investigator  will  inform  Medtronic  and  provide  a detailed  written  explanation  of the 
termination or suspension within 5 business  days.  
• Subject enrollment must stop until the s uspension is  lifted.  
• Subjects  already  enrolled  should  continue  to be followed  in accordance  with  IRB/REB/MEC 
policy  or its determination  if an overriding  safety  concern  or ethical  issue  is involved.  
• The  Investigator  will  inform  his/her  institution  (where  required  per  local  requirements).  
• The Investigator will promptly inform the subjects (or legally -authorized designees as 
allowed  by [CONTACT_169291])  and/or  the  personal  physician  of the  subjects,  with  the  rationale  for the 
study termination or  suspension.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 96 of 111   
  
• The Investigator will promptly inform the regulatory authorities (where required  per 
regulatory  requirements).  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 97 of 111   
  
 
 
• Calkins H, et al. HRS/EHRA/ECAS Expert Consensus Statement on Catheter and  Surgical 
Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and 
Follow -Up. Europace . 2007;9(6):335 -379.  
• Calkins H, et al., 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and 
Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural 
Techniques,  Patient  Management  and  Follow -up, Definitions,  Endpoints,  and  Research  Trial 
Design. Heart Rhythm  2012;9:632 -696.  
• Calkins H, et al., 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement 
on Catheter and Surgical Ablation of Atrial Fibrillation, Heart Rhythm (2017), 
doi:10.[ZIP_CODE]/j.hrthm.2017.05.012.  
• Ghanbari H, et al. Mo rtality and cerebrovascular events after  radiofrequency catheter 
ablation of atrial fibrillation. Heart Rhythm.  2014;11:1503 -1511.  
• Go A, et al. Prevalence of Diagnosed Atrial Fibrillation in Adults: National Implications for 
Rhythm  Management  and  Stroke  Prevention:  the  AnTicoagulation  and  Risk  Factors  In Atrial 
Fibrillation (ATRIA) Study. JAMA. 2001; 285(18):  2370 -2375.  
• Jais P, et al.  Stepwise Catheter Ablation of Chronic Atrial Fibrillation: Importance of 
Discrete Anatomic Sites for Termination. J Cardiovasc Electrophysiol. 2006;17: S28 -S36, 
Suppl.  3. 
• January C, et al. 2014 AHA/ACC/HRS guideline for the management of patients  with atr ial 
fibrillation: a report of the American College of Cardiology/American Heart Association 
Task  Force  on Practice  Guidelines  and  the  Heart  Rhythm  Society.  J Am  Coll  Cardiol.  2014.  
• Kirchof  and  Calkins.  Catheter  ablation  in patients  with  persistent  atrial  fibrillation.  European 
Heart J.  doi:10.1093/eurheartj/ehw260.  
• Raviele, et al. Venice Chart International Consensus Document on Atrial Fibrillation: 2011 
Update.  J Cardiovasc Electrophysiol,  2012;23:890 -923.  
• Rostock T, et al. Chronic Atrial Fibrillation Is  a Biatrial Arrhythmia Data from Catheter 
Ablation  of Chronic  Atrial  Fibrillation  Aiming  Arrhythmia  Termination  Using  a Sequential 
Ablation Approach. Circ Arrhythmia Electrophysiol.  2008;1:344 -353.  
• Verma  A, et  al. 2014  Focused  Update  of the  Canadian  Cardiovascular  Society  Guidelines  for 
the Management of Atrial Fibrillation. Canadian Journal of  Cardiology. 2014;30:1114 -1130.  
• Verma A, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J 
Med 2015;  372:1812 -1822.  
• Winkle RA. How much ablation to eliminate atrial fibrillation: Is less more  or is more more? 
Heart Rhythm. Epub ahead of print. DOI:  http://dx.doi.org/10.1016/j.hrthm.2015.06.031  
• Wolf  P, et al. Atrial  fibrillation  as an independent  risk  factor  for stroke:  the  Framingham 
Study. Stroke.  1991;22(8):983 -988.  15.  References  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 98 of 111   
  
• Zaker i et al. The  burden  of proof:  The  current  state  of atrial  fibrillation  prevention  and 
treatment trials. Heart Rhythm.  2017;14:763 -782.  
• Zoni -Berisso  M, et al. Epi[INVESTIGATOR_169250]:  European  perspective.  Clinical 
Epi[INVESTIGATOR_623]. 2014;6:213 -220.  doi:10.2147/CLEP.S47385.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 99 of 111   
  
 
 
Appendix A: CryoConsole Investigational Label  
CryoConsoles used in the study will have investigational software installed, a Catheter File, to allow 
for use of the ArcticLine Catheter. These CryoConsoles will have a console label affixed to the 
exterior that denotes the presence of investigational sof tware. As the study will be conducted in 
both Canada and US, the label will be in both French and English and consist of the following 
language:  
CAUTION / ATTENTION  
CryoConsole 106A3  
This CryoConsole is used for: ArcticLine Feasibility Study  
Cette CryoCons ole est utilisée pour l’étude clinique: ArcticLine Feasibility Study  
 
One (1) Investigational ArcticLine Catheter File (software) installed. 
(in         addition         to         other,         commercially         available,         software) 
Un (1) fic hier de recherche “ArcticLine Catheter File” (logiciel) installé. 
(en plus d’autres logiciels commerciaux)  
 
ArcticLine Catheter File:  
Exclusively for clinical investigations / Exclusivement pour l’investigation clinique  
To be used by [CONTACT_169300] / Réservé uniquement à l’usage de chercheurs qual  
CAUTION: Federal Law ([LOCATION_003]) restricts this device to sale by [CONTACT_35537] a physician. 
CAUTION: Investigational Device. Limited by [CONTACT_142193] ([LOCATION_003]) to investigational use.  
 
For questions, contact [CONTACT_737]:  
En cas de questions, contact[CONTACT_169301]:  
 
 
 
See ArcticLine Instructions for Use for more details.  
Voir les Instructions d’utilisation du cathéter ArcticLine pour plus d’information.  
 
Medtronic CryoCath LP  
9000 Autoroute Transcanadienne 
Pointe -Claire, Quebec, H9R 5Z8 
Canada  16.  Appendices  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 100 of 111   
  
Appendix B: Instructions For Use  
Always reference the current version of the Instructions For Use document as provided by 
[CONTACT_169302].  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 101  of 111   
  
Appendix C: Foreseeable Adverse Events  
The information provided in this section pertains to foreseeable adverse events that may be 
observed in study subjects and may collectively assist in identifying those events for a given device 
or therapy that are une xpected in nature.  
 
The cryoablation procedure involves surgery, therefore, standard adverse events associated with 
a surgical procedure may be experienced (e.g. anesthesia complications, injury, infections, 
bleeding, exacerbation of pre -existing conditions, healing complicat ions). The focus of this section 
is to specifically address in mored etail, those events that are foreseeable due to the use, 
performance, and/or presence of the ArcticLine Catheter under investigation.  
 
Treatment required for procedure and/or cryoablation system related adverse events that are 
experienced may include medication or other surgical and medical remedies. The adverse events 
associated with the use of the ArcticLine Catheter include but are not  limited to those in Table 14 . 
 
Table 14  pertains to the foreseeable/anticipated adverse events that may be observed in the study 
and may assist in identifying those adverse events that are un expected in nature.  
 
Table 14: Foreseeable adverse events  
 
Adverse Event/Risk  Definition  
Access site complications (e.g. 
bruising, ecchymosis)  Complications at catheter insertion site in the groin  
Anemia  Deficiency of red blood cells or of hemoglobin in the blood 
resulting in weariness  
Anxiety  Feeling of worry, nervousness, or unease  
Arrhythmia (e.g. atrial flutter, 
bradycardia, heart block, 
tachycardia)  Disruption of normal heart rate or rhythm  
Back pain  Pain felt in the lower or upper back  
Bleeding, possibly requiring 
transfusion  Loss of blood, including loss resulting in transfusion  
Bronchitis  Inflammation of the lining of bronchial tubes that carry air to 
and from the lungs  
Cardiac tamponade  Pressure on the heart as a result of fluid collecting in the sac 
surrounding the heart  
Cardiopulmonary arrest  Cessation of blood circulation and/or respi[INVESTIGATOR_169251]/or lungs  
Catheter entrapment in cardiac 
structures requiring intervention  Tangling of the catheter in the heart which requires invasive 
intervention, including surgical repair  
Cerebral vascular accident  Blockage of blood flow, or rupture of an artery, to the brain  
which causes sudden death of brain cells  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 102  of 111   
  
Adverse Event/Risk  Definition  
Chest discomfort/pain/pressure  Includes a range of feeling from sharp stabbing to dull ache 
in the chest  
Cold feeling  Having a low or inadequate temperature  
Coronary artery spasm  Temporary constriction of a coronary artery, including ECG 
evidence reflecting ST segment abnormally high above 
baseline  
Cough  Rapid expulsion of air from the lungs  
Death  Complication or deterioration of health ultimately leading to  
a patient’s death  
Diarrhea  Feces discharged from the bowels frequently and in a liquid 
form  
Dizziness  Feeling faint, woozy, weak or unsteady  
Embolism  Formation and dislodgement of a blood clot (thrombus) or 
dislodgement of cholesterol/plaque within the blood vessel, 
which travels downstream into small vessels, blocking blood 
flow and causing temporary or permanent damage to 
organs distal to blockage. Em boli are known to cause 
myocardial infarction, transient ischemic attack, 
stroke/cardiovascular accident, blurred vision, visual 
changes, paralysis, paresis, or kidney damage, peripheral 
ischemia and may ultimately lead to incapacitation or death. 
Symptoma tic and non -symptomatic.  
Esophageal damage (including 
atrioesophageal fistula)  Damage to the esophagus, including ulcer and 
atrioesophageal fistula (an abnormal passageway between 
the heart and esophagus)  
Fatigue  Extreme tiredness  
Fever  Abnormally high body temperature  
Headache  Pain in the head  
Hemoptysis  Coughing up blood or blood -stained mucus  
Hypotension/hypertension  Low/high blood pressure  
Infection (e.g. sepsis)  Invasion and multiplication of microorganisms (e.g. bacteria, 
virus) not normally present within the body  
Lightheadedness  Feeling faint, woozy, weak or unsteady  
Myocardial infarction  Blockage of blood flow to the heart muscle (i.e. heart attack)  
Nausea/vomiting  • Nausea: sensation of unease and discomfort in the 
upper stomach with an urge to  vomit  
• Vomiting: forceful expulsion of stomach contents 
through the mouth and/or  nose  
Perforation  Unintended puncture through the wall of a blood vessel or 
cardiac tissue  
Pericardial effusion  Fluid collecting in the sac that surrounds the heart  
Pericarditis  Inflammation of the sac -like tissue that surrounds the heart  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 103  of 111   
  
Adverse Event/Risk  Definition  
Phrenic nerve injury  Damage to the nerve that controls breathing; may cause 
hiccups, involuntary spasm of the diaphragm and 
respi[INVESTIGATOR_54374], or paralyze the diaphragm  
Pleural effusion  Collection of extra fluid around the lungs  
Pneumonia  Lung infection that inflames air sa cs in one or both lungs  
Pneumothorax  Collapsed lung  
Pseudoaneurysm  Collection of blood in the tissue surrounding the catheter 
insertion site due to ongoing leaking of blood from a blood 
vessel  
Pulmonary edema  Excess fluid in the lungs  
Pulmonary vein stenosis  Blockage in the blood vessels takes blood from the lungs to 
the heart  
Shortness of breath  Difficulty breathing  
Shivering  Body shaking  
Sore throat  Pain in throat  
Transient ischemic attack  New focal neurological deficit with rapid symptom 
resolution (usually 1 to 2 hours), no more than 24 hours  
Vagal nerve injury (e.g. 
gastroparesis)  Injury to the vagal nerve resulting in esophageal dysmotility 
or gastroparesis, including:  
• Delayed gastric  emptying  
• Difficulty swallowing/narrowing of the  esophagus  
• Digestive discomfort/pain in the  abdomen  
Valve damage with potential 
regurgitation  Damage to heart valve (e.g. tricuspid, mitral), including 
backward flow of blood through the valve  
Vasovagal reaction  Reflex of the involuntary nervous system that causes the 
heart to slow down and blood pressure drops; may result in 
fainting  
Visual changes  Changes to vision, including blurred vision and bilateral 
visual disturbance  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 104  of 111   
  
Appendix D: Endpoint -Related Adverse Event Definitions  
Table 15  describes definitions for a subset of endpoint -related adverse events that may be 
observed in the study.  
 
Table 15: Adverse Event Definitions  
 
Adverse Event  Definition  
Atrioesophageal Fistula  Connection between the atrium and the lumen of the esophagus. 
Evidence supporting this diagnosis includes documentation of 
esophageal erosion combined with evidence of a fistulous connection 
to the atrium such as air emboli, an embolic event, or direct 
observation at the time of surgical repair.  
Cardiac tamponade/ 
perforation  Development of a significant pericardial effusion during or within 30 
days of undergoing the study ablation procedure. A significant 
pericardial effusion is one that results in hemodynamic compromise, 
requires elective or urg ent pericardiocentesis, or results in a 1 -cm or 
more pericardial effusion as documented by [CONTACT_51541].  
Cerebrovascular 
accident/stroke  Rapid onset of a focal or global neurological deficit with at least one of 
the following: change in level of consc iousness, hemiplegia, 
hemiparesis,  
numbness or sensory loss affecting one side of the body, dysphasia or 
aphasia, hemianopia, amaurosis fugax, or other neurological signs or 
symptoms consistent with stroke. Confirmed by [CONTACT_169303]/or radiographic confirmation.  
Esophageal inju ry Injury to the lumen of the esophagus that does not result in an 
atrioesophageal fistula. Confirmed by [CONTACT_169304].  
Hemoptysis  Expectoration of blood or blood -tinged sputum from the lungs or 
tracheobronchial tree.  
Lung Injury  Presence of any of the following: bronchial lesion, hemoptysis, 
constriction, pulmonary hemorrhage, bronchia fistula  
Major bleeding  Bleeding that requires and/or is treated with transfusion or results in a 
20% or greater fall in hematocrit.  
Myocardial infarction  Presence of any one of the following criteria:  
1) detection of ECG changes indicative of new ischemia (new 
ST-T changes or new LBBB), which persist for more than one 
hour;  
2) development of new pathological Q waves on an  ECG;  
3) imaging evidence of new loss of viable myocardium or  new 
regional wall motion  abnormality.  
Pericarditis  Effusion that leads to hemodynamic compromise or requires 
pericardiocentesis, prolongs hospi[INVESTIGATOR_169252] 48 hours, 
requires hospi[INVESTIGATOR_059],  or persists for more than 30 days following 
the ablation procedure.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 105  of 111   
  
Adverse Event  Definition  
Phrenic nerve injury  Absent phrenic nerve function as assessed by [CONTACT_169305]/sniff test that is ongoing from hospi[INVESTIGATOR_2345]. 
Phrenic nerve injury is considered permanent when it is documented 
to be present 12 months or longer following ablation.  
Pulmonary v ein 
stenosis  Reduction of the diameter of a PV or PV branch. PV  stenosis can be 
categorized as mild <50%, moderate 50% –70%, and severe ≥70% 
reduction in the diameter of the PV or PV  branch.  
Symptomatic 
persistent iatrogenic 
atrial septal defect  New atrial septal defect found by [CONTACT_169306] -set pulmonary hypertension 
(symptomatic) and assessed via ultrasound Doppler imaging.  
Transient ischemic 
attack  New focal neurological deficit with rapid sympt om resolution (usually 
1 to 2 hours), no more than 24 hours. Confirmed by [CONTACT_169303]/or radiographic confirmation.  
Vagal nerve injury  Injury to the vagal nerve that results in esophageal dysmotility or 
gastroparesis (i.e. delayed gastric emptying).  
Vascular access site 
complication  Development of a hematoma (excluding minor hematomas not 
requiring surgical treatment), AV fistula or pseu doaneurysm that 
requires intervention, prolongs the hospi[INVESTIGATOR_4408], or requires hospi[INVESTIGATOR_15517].  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 106  of 111   
  
Appendix E: Draft Data Collection Elements (Case Report Forms)  
Draft CRFs for the study will be provided under separate cover. Final CRFs will be provided to 
centers via the electronic data management system after the center has fulfilled all requirements 
for database access.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 107  of 111   
  
Appendix F: Informed Consen t Template  
The Informed Consent Template will be distributed under separate cover.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 108  of 111   
  
Appendix G: IRB/REB/MEC List  
A final IRB/REB/MEC list has not been finalized prior to development of the Clinical Investigator 
Plan and will be distributed un der separate cover.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 109  of 111   
  
Appendix H: Participating Investigators and Institutions  
A final list of participating Investigators and institutions has not been finalized prior to 
development of the Clinical Investigation Plan and will be distributed under separate cover.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation  Plan  
Version 1.0,  14JUN2017  Page 110 of 111   
  
Appendix I: Pre -Clinical Testing  
A summary of results from pre -clinical testing with the ArcticLine Catheter is provided in the 
Report of Prior Investigations Summary under separate cover.  
Medtronic Confidential  
056-F275, v3.0 Clinical Investigation Plan Template  This document is electronically controlled  ArcticLine Feasibility Study Clinical Investigation Plan  
Version 1.0,  14JUN2017  Page 111 of 111   
  
 
 
Version  Summary of Changes  Author(s)/Title  
1.0 • Not Applicable, New  Document  Mandi Rupp, Principal Clinical 
Research Specialist  
Jeff Cerkvenik, Senior Principal 
Statistician  
Kirsten Rasmussen, Clinical 
Research Specialist  
Craig Dull, Principal Field Clinical 
Engineer  
 17.  Version  History  